| Year |
Citation |
Score |
| 2023 |
Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao ZK, Ouerfelli O, Liu H, Stockwell BR, Campesato LF, Zamarin D, Zappasodi R, Wolchok JD, et al. APR-246 increases tumor antigenicity independent of p53. Life Science Alliance. 7. PMID 37891002 DOI: 10.26508/lsa.202301999 |
0.334 |
|
| 2023 |
Yang N, Wang Y, Liu S, Tariq SB, Luna JM, Mazo G, Tan A, Zhang T, Wang J, Yan W, Choi J, Rossi A, Xiang JZ, Rice CM, Merghoub T, ... Wolchok JD, et al. OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. The Journal of Experimental Medicine. 220. PMID 37145142 DOI: 10.1084/jem.20221166 |
0.307 |
|
| 2023 |
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, ... ... Wolchok JD, et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 186: 1432-1447.e17. PMID 37001503 DOI: 10.1016/j.cell.2023.03.007 |
0.37 |
|
| 2022 |
Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho YJ, Campesato LF, Mangarin L, Fak J, Suek N, Holland A, Liu C, Abu-Akeel M, ... ... Wolchok JD, et al. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. The Journal of Clinical Investigation. 132. PMID 36106631 DOI: 10.1172/JCI148141 |
0.31 |
|
| 2022 |
Kraehenbuehl L, Holland A, Armstrong E, O'Shea S, Mangarin L, Chekalil S, Johnston A, Bomalaski JS, Erinjeri JP, Barker CA, Francis JH, Wolchok JD, Merghoub T, Shoushtari AN. Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers. 14. PMID 35681616 DOI: 10.3390/cancers14112638 |
0.373 |
|
| 2022 |
Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, ... ... Wolchok JD, et al. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications. 13: 1935. PMID 35410325 DOI: 10.1038/s41467-022-29342-0 |
0.33 |
|
| 2021 |
Gupta A, Budhu S, Fitzgerald K, Giese R, Michel AO, Holland A, Campesato LF, van Snick J, Uyttenhove C, Ritter G, Wolchok JD, Merghoub T. Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Communications Biology. 4: 1296. PMID 34789823 DOI: 10.1038/s42003-021-02773-z |
0.3 |
|
| 2021 |
Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. Jci Insight. 6. PMID 34676831 DOI: 10.1172/jci.insight.151035 |
0.344 |
|
| 2021 |
Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, Keegan N, Funt SA, Iyer G, Rosenberg JE, ... ... Wolchok JD, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine. 13. PMID 34433638 DOI: 10.1126/scitranslmed.abf5107 |
0.356 |
|
| 2021 |
Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA. TMB and Inflammatory Gene Expression Associated With Clinical Outcomes Following Immunotherapy in Advanced Melanoma. Cancer Immunology Research. PMID 34389558 DOI: 10.1158/2326-6066.CIR-20-0983 |
0.319 |
|
| 2021 |
Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, Knorr DA, Greenbaum B, Elhanati Y, Hogg SJ, Chow A, Ghosh A, Xie A, Zamarin D, Cui D, ... ... Wolchok JD, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. PMID 34171309 DOI: 10.1016/j.cell.2021.05.038 |
0.307 |
|
| 2021 |
Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, ... ... Wolchok JD, et al. Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. Cancer Cell. PMID 34115989 DOI: 10.1016/j.ccell.2021.05.006 |
0.373 |
|
| 2021 |
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, ... ... Wolchok JD, et al. CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine. PMID 34017137 DOI: 10.1038/s41591-021-01386-7 |
0.311 |
|
| 2021 |
Slingluff CL, Zarour HM, Tawbi HA, Kirkwood JM, Postow MA, Friedlander P, Devoe CE, Gaughan EM, Mauldin IS, Olson WC, Smith KT, Macri MJ, Ricciardi T, Ryan A, Venhaus R, ... Wolchok JD, et al. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 10: 1898105. PMID 33796406 DOI: 10.1080/2162402X.2021.1898105 |
0.396 |
|
| 2021 |
Huang A, Bange E, Han N, Wileyto EP, Kim J, Gouma S, Robinson J, Greenplate A, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman A, Ittner C, ... ... Wolchok JD, et al. CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Research Square. PMID 33564756 DOI: 10.21203/rs.3.rs-162289/v1 |
0.301 |
|
| 2021 |
Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LF, De Henau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, et al. Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Reports. 34: 108620. PMID 33440157 DOI: 10.1016/j.celrep.2020.108620 |
0.358 |
|
| 2021 |
Smithy JW, Pianko MJ, Maher C, Postow MA, Shoushtari AN, Momtaz P, Chapman PB, Wolchok JD, Park JH, Callahan MK. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia. Journal of Immunotherapy (Hagerstown, Md. : 1997). 44: 9-15. PMID 33290361 DOI: 10.1097/CJI.0000000000000345 |
0.359 |
|
| 2020 |
Li J, Duran MA, Dhanota N, Chatila WK, Bettigole SE, Kwon J, Sriram RK, Humphries MP, Salto-Tellez M, James JA, Hanna MG, Melms JC, Vallabhaneni S, Litchfield K, Usaite I, ... ... Wolchok JD, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discovery. PMID 33372007 DOI: 10.1158/2159-8290.CD-20-0387 |
0.316 |
|
| 2020 |
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, ... ... Wolchok JD, et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. PMID 32916126 DOI: 10.1016/J.Ccell.2020.08.005 |
0.415 |
|
| 2020 |
Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, Zappasodi R, Zamarin D, Cavanaugh J, Castro AC, Manfredi MG, ... ... Wolchok JD, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications. 11: 4011. PMID 32782249 DOI: 10.1038/S41467-020-17750-Z |
0.435 |
|
| 2020 |
Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS, Joanow A, Kaltsas A, Lee YJ, Lucca A, Mariano A, ... ... Wolchok JD, et al. Determinants of COVID-19 disease severity in patients with cancer. Nature Medicine. PMID 32581323 DOI: 10.1038/S41591-020-0979-0 |
0.331 |
|
| 2020 |
Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabrò L, Vardana SA, Robert C, Ibrahim R, Anichini A, Wolchok JD, Di Giacomo AM. Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32540850 DOI: 10.1158/1078-0432.Ccr-20-1657 |
0.37 |
|
| 2020 |
Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research. 30: 507-519. PMID 32467593 DOI: 10.1038/S41422-020-0337-2 |
0.397 |
|
| 2020 |
Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discovery. PMID 32398243 DOI: 10.1158/2159-8290.Cd-20-0596 |
0.319 |
|
| 2020 |
Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. The Journal of Experimental Medicine. 217. PMID 32353870 DOI: 10.1084/Jem.20200678 |
0.306 |
|
| 2020 |
Postow MA, Knox SJ, Goldman DA, Elhanati Y, Mavinkurve V, Wong P, Halpenny DF, Reddy SA, Vado KP, McCabe D, Ramirez KA, Macri M, Schwarzenberger P, Ricciardi T, Ryan A, ... ... Wolchok JD, et al. A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32205463 DOI: 10.1158/1078-0432.Ccr-19-3936 |
0.387 |
|
| 2020 |
Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, Askan G, Bhanot U, Elyada E, Park Y, Tuveson DA, ... ... Wolchok JD, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. PMID 32076273 DOI: 10.1038/S41586-020-2015-4 |
0.414 |
|
| 2020 |
Wang H, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, Mohmood SR, Fernández-García J, Tsai CH, Schulze I, Picard F, Meylan E, Silverstein R, Goldberg I, Fendt SM, ... Wolchok JD, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology. PMID 32066953 DOI: 10.1038/S41590-019-0589-5 |
0.416 |
|
| 2020 |
Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK, Wolchok JD, Postow MA, Chapman PB. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901464. PMID 32053428 DOI: 10.1200/Jco.19.01464 |
0.37 |
|
| 2020 |
Holm JS, Funt SA, Bjerregaard A, Reading JL, Maher CA, Regazzi AM, Wong P, Al-Ahmadie H, Overgaard NH, Tamhane T, Bentzen AK, Snyder A, Merghoub T, Wolchok JD, Nielsen M, et al. Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 38: 3075-3075. DOI: 10.1200/Jco.2020.38.15_Suppl.3075 |
0.413 |
|
| 2020 |
Campesato LF, Budhu S, Gigoux M, Tchaicha J, Pourpe S, Liu C, Zamarin D, Manfredi MG, McGovern K, Wolchok JD, Merghoub T. Abstract PR05: Blockade of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr05 |
0.431 |
|
| 2020 |
Wolchok J. Abstract IA24: Immune-modulating approaches to cancer therapy: Focusing on combinations Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Ia24 |
0.478 |
|
| 2020 |
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, Donoghue MTA, Łuksza M, Greenbaum BD, Wolchok JD, Kris MG, Hellmann MD. Abstract IA04: COVID-19 in patients with lung cancers in New York City Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Covid-19-Ia04 |
0.333 |
|
| 2020 |
Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong K, Wolchok JD. Abstract 923: Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer Immunology. 80: 923-923. DOI: 10.1158/1538-7445.Am2020-923 |
0.478 |
|
| 2020 |
Arniella M, Ravi A, Stewart C, Freeman S, Awad M, Forde P, Anagnostou V, Henick B, Riess J, Gibbons D, Pennell N, Velcheti V, Leshchiner I, Kim J, Digumarthy S, ... ... Wolchok J, et al. Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative Cancer Research. 80: 5902-5902. DOI: 10.1158/1538-7445.Am2020-5902 |
0.356 |
|
| 2020 |
Zappasodi R, Serganova I, Cohen I, Maeda M, Shindo M, Senbabaoglu Y, Leftin A, Maniyar R, Verma S, Lubin M, Ko MK, Mane MM, Ghosh A, Ackerstaff E, Koutcher JA, ... ... Wolchok JD, et al. Abstract 3257: CTLA-4 blockade drives loss of regulatory T cell functional stability in glycolysis defective tumors Immunology. 80: 3257-3257. DOI: 10.1158/1538-7445.Am2020-3257 |
0.452 |
|
| 2020 |
Chow A, Schad S, Green M, Hellmann M, Ceglia N, Allaj V, Zago G, Shah N, Sharma S, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, ... ... Wolchok J, et al. 524 Tim-4+ resident macrophages impair anti-tumor immunity in the serous body cavities By sequestering viable and cytotoxic CD8+ T cells expressing high levels of phosphatidylserine Journal For Immunotherapy of Cancer. 8: A560-A560. DOI: 10.1136/jitc-2020-sitc2020.0524 |
0.341 |
|
| 2019 |
Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology. PMID 31848819 DOI: 10.1245/S10434-019-08099-9 |
0.357 |
|
| 2019 |
Francis JH, Berry D, Abramson DH, Barker CA, Bergstrom C, Demirci H, Engelbert M, Grossniklaus H, Hubbard B, Iacob CE, Jaben K, Kurli M, Postow MA, Wolchok JD, Kim IK, et al. Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. Ophthalmology. PMID 31708274 DOI: 10.1016/J.Ophtha.2019.09.018 |
0.351 |
|
| 2019 |
Pandit-Taskar N, Postow M, Hellmann M, Harding J, Barker C, O'Donoghue J, Ziolkowska M, Ruan S, Lyashchenko S, Tsai F, Farwell M, Mitchell T, Korn R, Le W, Lewis J, ... ... Wolchok J, et al. First-in-human imaging with Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31586002 DOI: 10.2967/Jnumed.119.229781 |
0.381 |
|
| 2019 |
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, ... ... Wolchok JD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine. PMID 31562797 DOI: 10.1056/Nejmoa1910836 |
0.339 |
|
| 2019 |
Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, Nishikawa H. Selective inhibition of low-affinity memory CD8 T cells by corticosteroids. The Journal of Experimental Medicine. PMID 31537643 DOI: 10.1084/Jem.20190738 |
0.43 |
|
| 2019 |
Callahan MK, Wolchok JD. Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes? Cancer Cell. 36: 215-217. PMID 31526757 DOI: 10.1016/J.Ccell.2019.08.009 |
0.379 |
|
| 2019 |
Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900345. PMID 31498030 DOI: 10.1200/Jco.19.00345 |
0.341 |
|
| 2019 |
Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Research. PMID 31425479 DOI: 10.1097/Cmr.0000000000000633 |
0.354 |
|
| 2019 |
Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer (Oxford, England : 1990). 119: 1-10. PMID 31400634 DOI: 10.1016/J.Ejca.2019.07.001 |
0.343 |
|
| 2019 |
Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June CH, Wherry EJ, Zhang NR, Ishwaran H, Hellmann MD, Wolchok JD, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 178: 933-948.e14. PMID 31398344 DOI: 10.1016/J.Cell.2019.07.019 |
0.454 |
|
| 2019 |
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, ... ... Wolchok J, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. Nature Immunology. PMID 31358999 DOI: 10.1038/S41590-019-0441-Y |
0.338 |
|
| 2019 |
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. Jama Oncology. PMID 31343665 DOI: 10.1001/Jamaoncol.2019.2187 |
0.347 |
|
| 2019 |
Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, Hirschhorn D, Zappasodi R, Giese R, Gasmi B, Schneider M, ... ... Wolchok JD, et al. In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of Clinical Investigation. 130. PMID 31329159 DOI: 10.1172/Jci128562 |
0.446 |
|
| 2019 |
Lebdai S, Gigoux M, Alvim R, Somma A, Nagar K, Azzouzi AR, Cussenot O, Merghoub T, Wolchok JD, Scherz A, Kim K, Coleman J. Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. Oncoimmunology. 8: e1581528. PMID 31069149 DOI: 10.1080/2162402X.2019.1581528 |
0.413 |
|
| 2019 |
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, ... ... Wolchok JD, et al. Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. PMID 31036879 DOI: 10.1038/S41591-019-0420-8 |
0.469 |
|
| 2019 |
Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong KK, Wolchok JD. Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports. 27: 806-819.e5. PMID 30995478 DOI: 10.1016/J.Celrep.2019.03.066 |
0.462 |
|
| 2019 |
Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30923036 DOI: 10.1158/1078-0432.Ccr-18-1550 |
0.455 |
|
| 2019 |
Lee Chuy K, Oikonomou EK, Postow MA, Callahan MK, Chapman PB, Shoushtari AN, Neilan TG, Fradley MG, Ramanathan LV, Wolchok JD, Steingart RM, Gupta D. Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. The Oncologist. PMID 30910868 DOI: 10.1634/Theoncologist.2019-0040 |
0.361 |
|
| 2019 |
Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors (ICI). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30874791 DOI: 10.1093/Cid/Ciz202 |
0.336 |
|
| 2019 |
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, ... ... Wolchok JD, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics. PMID 30643254 DOI: 10.1038/S41588-018-0312-8 |
0.405 |
|
| 2019 |
Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. Cancer Immunology, Immunotherapy : Cii. 68: 1-9. PMID 30564889 DOI: 10.1007/S00262-018-2285-Y |
0.37 |
|
| 2019 |
Keegan NM, Funt SA, Kania BE, Iyer G, Clement JM, McCoy AS, Hettich G, Ziv E, Maher CA, Nair S, Panageas K, Bluth MJ, Wong P, Wolchok JD, Rosenberg JE, et al. Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 37: 481-481. DOI: 10.1200/Jco.2019.37.7_Suppl.481 |
0.336 |
|
| 2019 |
Atkins MB, Kirkwood JM, Wolchok JD, Callahan MK, Kluger HM, Postow MA, Segal NH, Lesokhin AM, Balogh A, Re S, Sznol M. Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma. Journal of Clinical Oncology. 37: 9533-9533. DOI: 10.1200/Jco.2019.37.15_Suppl.9533 |
0.317 |
|
| 2019 |
Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas K, Callahan MK, Wolchok JD, Postow MA, Chapman PB. Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel). Journal of Clinical Oncology. 37: 9513-9513. DOI: 10.1200/Jco.2019.37.15_Suppl.9513 |
0.35 |
|
| 2019 |
Funt SA, Jatwani K, Makris M, Regazzi AM, Lee C, Teo MY, McHugh DJ, McCoy AS, Hettich G, Wong P, Abu-Akeel M, Wolchok JD, Merghoub T, Al-Ahmadie H, Ostrovnaya I, et al. A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 37: 4559-4559. DOI: 10.1200/Jco.2019.37.15_Suppl.4559 |
0.351 |
|
| 2019 |
Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. Journal of Clinical Oncology. 37: 2512-2512. DOI: 10.1200/Jco.2019.37.15_Suppl.2512 |
0.304 |
|
| 2019 |
Weber JS, Tang H, Hippeli L, Qian M, Wind-Rotolo M, Larkin JM, Wolchok JD, Sznol M, Robert C, Woods DM, Laino AS, Hodi FS. Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. Journal of Clinical Oncology. 37: 100-100. DOI: 10.1200/Jco.2019.37.15_Suppl.100 |
0.317 |
|
| 2019 |
Deng L, Yang N, Wang Y, Yan W, Wang J, Choi J, Shuman S, Merghoub TD, Wolchok JD. Abstract PR09: Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for "in situ" therapeutic cancer vaccination Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr09 |
0.455 |
|
| 2019 |
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Postow M, ... ... Wolchok JD, et al. Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr01 |
0.513 |
|
| 2019 |
Choi H, Deng J, Li S, Silk T, Brea EJ, Boiarsky J, Akbay EA, Smith PD, Merghoub TD, Wong K, Wolchok JD. Abstract A125: Pulsatile MEK inhibition improves antitumor immunity and T-cell function in Kras mutant lung cancer Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A125 |
0.451 |
|
| 2019 |
Callahan MK, Odunsi K, Sznol M, Nemunaitis J, Ott PA, Dillon P, Schneider R, Park A, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Venhaus R, Wolchok JD. Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A006 |
0.46 |
|
| 2019 |
Drozdz MM, Wang J, Reilly M, Kane E, Aguirre K, Doane A, Wolchok JD, Elemento O, Desman G, Merghoub T, Piskounova E, Zippin J. Abstract LB-081: A nuclear cAMP microdomain functions as a tumor suppressor in melanoma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-081 |
0.312 |
|
| 2019 |
Chow A, Schad S, Sharma SK, Budhu S, Gupta A, Pimentel C, Zhong H, Lewis JS, Poirier JT, Wolchok JD, Rudin CM, Merghoub T. Abstract 978: Tim-4+tissue-resident macrophages impair antitumor T-cell immunity Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-978 |
0.344 |
|
| 2019 |
Haimovitz-Friedman A, Humm J, Deasy JO, Wolchok J, Merghoub T, Russell J, Li H, Samstein R, Budhu S, Powell S, Bodden C, Markovsky E, Chen Q. Abstract 3735: An anti-tumor immune response is evoked by partial-volume single dose radiation Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3735 |
0.351 |
|
| 2019 |
Leung J, Rojas LA, Ruan J, Zhao J, Gasmi B, Sethna Z, Ramnarain A, Bhanot U, Askan G, Gururajan M, Elyada E, Park Y, Tuveson DA, Gonen M, Leach SD, ... Wolchok JD, et al. Abstract B02: Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B02 |
0.423 |
|
| 2019 |
Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Qian M, Saci A, Young TC, Srinivasan S, Chang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA. Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct037 |
0.344 |
|
| 2019 |
Ghosh A, Michel J, Dong L, Suek N, Zhong H, Budhu S, Henau Od, Wolchok J, Merghoub T. Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models Cancer Research. 79: 4843-4843. DOI: 10.1158/1538-7445.Am2019-4843 |
0.477 |
|
| 2019 |
Caushi JX, Ji Z, Zhang J, Asmar ME, Anagnostou V, Cottrell TR, Chan HY, Guo H, Merghoub T, Wolchok JD, Naidoo J, Marrone KA, Chaft JE, Hellmann MD, Gabrielson E, et al. Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC Cancer Research. 79: 4041-4041. DOI: 10.1158/1538-7445.Am2019-4041 |
0.446 |
|
| 2019 |
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Callahan MK, ... Wolchok J, et al. Abstract 2711: Rational combination of GITR agonism with PD-1 blockade Cancer Research. 79: 2711-2711. DOI: 10.1158/1538-7445.Am2019-2711 |
0.488 |
|
| 2019 |
Zappasodi R, Heath H, Zhang Y, Haas M, Yang M, Mirabelli C, Wolchok JD, Sirard C, Newman W, Merghoub T. Abstract 2402: GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human Cancer Research. 79: 2402-2402. DOI: 10.1158/1538-7445.Am2019-2402 |
0.364 |
|
| 2019 |
Larkin JMG, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao C, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, ... ... Wolchok J, et al. 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.065 |
0.323 |
|
| 2019 |
Zhang J, Ji Z, Caushi J, Asmar ME, Anagnostou V, Cottrell T, Chan HY, Guo H, Merghoub T, Chaft J, Wolchok J, Reuss J, Marrone K, Naidoo J, Gabrielson E, et al. MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.590 |
0.358 |
|
| 2019 |
Caushi J, Ji Z, Zhang J, Asmar ME, Anagnostou V, Cottrell T, Chan HY, Guo H, Merghoub T, Wolchok J, Naidoo J, Marrone K, Chaft J, Hellmann M, Gabrielson E, et al. P2.04-24 Transcriptional Profiling of Neoantigen Specific T Cells in Resectable NSCLC Treated with Neoadjuvant Anti-PD-1 Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1529 |
0.358 |
|
| 2018 |
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao C, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill AG, Hogg D, Marquez-Rodas I, ... ... Wolchok J, et al. Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii735. PMID 32138018 DOI: 10.1093/Annonc/Mdy424.054 |
0.329 |
|
| 2018 |
Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, ... ... Wolchok JD, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Jama Oncology. PMID 30589920 DOI: 10.1001/Jamaoncol.2018.5801 |
0.381 |
|
| 2018 |
Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, et al. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6098. PMID 30510087 DOI: 10.1158/1078-0432.Ccr-18-3340 |
0.358 |
|
| 2018 |
Wolchok J. Putting the Immunologic Brakes on Cancer. Cell. 175: 1452-1454. PMID 30500529 DOI: 10.1016/J.Cell.2018.11.006 |
0.354 |
|
| 2018 |
Ito K, Schöder H, Teng R, Humm JL, Ni A, Wolchok JD, Weber WA. Prognostic value of baseline metabolic tumor volume measured on F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30488098 DOI: 10.1007/S00259-018-4211-0 |
0.327 |
|
| 2018 |
Ito K, Teng R, Schöder H, Humm JL, Ni A, Michaud L, Nakajima R, Yamashita R, Wolchok JD, Weber WA. F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30413661 DOI: 10.2967/Jnumed.118.213652 |
0.323 |
|
| 2018 |
Markovsky E, Budhu S, Samstein RM, Li H, Russell J, Zhang Z, Drill E, Bodden C, Chen Q, Powell SN, Merghoub T, Wolchok JD, Humm J, Deasy JO, Haimovitz-Friedman A. An Anti-Tumor Immune Response is Evoked By Partial-Volume Single Dose Radiation in Two Murine Models. International Journal of Radiation Oncology, Biology, Physics. PMID 30342090 DOI: 10.1016/J.Ijrobp.2018.10.009 |
0.356 |
|
| 2018 |
Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 34: 690. PMID 30300584 DOI: 10.1016/J.Ccell.2018.03.005 |
0.445 |
|
| 2018 |
Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Science Translational Medicine. 10. PMID 30232229 DOI: 10.1126/Scitranslmed.Aat7807 |
0.434 |
|
| 2018 |
Zappasodi R, Wolchok JD, Merghoub T. Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports. 13: 383-395. PMID 30159703 DOI: 10.1007/S11899-018-0471-9 |
0.408 |
|
| 2018 |
Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine. 10. PMID 30021886 DOI: 10.1126/Scitranslmed.Aar3342 |
0.437 |
|
| 2018 |
Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 9: 28702-28716. PMID 29983890 DOI: 10.18632/Oncotarget.25614 |
0.454 |
|
| 2018 |
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, ... ... Wolchok JD, et al. Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29982279 DOI: 10.1093/Annonc/Mdy218 |
0.41 |
|
| 2018 |
Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, Kim IS, Haldeman P, Mondal C, Yong-Gonzalez V, Abu-Akeel M, Merghoub T, Jones DR, Zhu XG, Arora A, ... ... Wolchok JD, et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins. Cancer Discovery. PMID 29903879 DOI: 10.1158/2159-8290.Cd-17-1371 |
0.325 |
|
| 2018 |
Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, ... Wolchok JD, et al. Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell. 33: 1017-1032.e7. PMID 29894689 DOI: 10.1016/J.Ccell.2018.05.009 |
0.384 |
|
| 2018 |
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, ... ... Wolchok JD, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery. PMID 29773717 DOI: 10.1158/2159-8290.Cd-18-0099 |
0.31 |
|
| 2018 |
Joseph RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud AI, Dronca RS, Hersey P, Weber JS, Patnaik A, et al. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29685882 DOI: 10.1158/1078-0432.Ccr-17-2386 |
0.379 |
|
| 2018 |
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, ... ... Wolchok JD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medicine. PMID 29658848 DOI: 10.1056/Nejmoa1716078 |
0.435 |
|
| 2018 |
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, ... ... Wolchok JD, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. PMID 29657128 DOI: 10.1016/J.Ccell.2018.03.018 |
0.4 |
|
| 2018 |
Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, ... ... Wolchok JD, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. PMID 29656892 DOI: 10.1016/J.Cell.2018.03.026 |
0.419 |
|
| 2018 |
Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 33: 581-598. PMID 29634946 DOI: 10.1016/j.ccell.2018.03.005 |
0.336 |
|
| 2018 |
Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, Breous-Nystrom E, Dupont C, Ward RA, Mundt C, Duckless B, Tang H, Findeis MA, Schuster A, Waight JD, ... ... Wolchok JD, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. Plos One. 13: e0191926. PMID 29617360 DOI: 10.1371/Journal.Pone.0191926 |
0.439 |
|
| 2018 |
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (New York, N.Y.). 359: 1350-1355. PMID 29567705 DOI: 10.1126/Science.Aar4060 |
0.477 |
|
| 2018 |
Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of Clinical Investigation. PMID 29504948 DOI: 10.1172/Jci98047 |
0.417 |
|
| 2018 |
Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, ... Wolchok JD, et al. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017757740. PMID 29489427 DOI: 10.1200/Jco.2017.75.7740 |
0.417 |
|
| 2018 |
Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29478729 DOI: 10.1016/J.Ymthe.2018.01.019 |
0.416 |
|
| 2018 |
Melero I, Sznol M, Tessmer MS, Whiteside TL, Wolchok JD. Introducing a New Series: Immunotherapy Facts and Hopes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29476022 DOI: 10.1158/1078-0432.Ccr-18-0408 |
0.395 |
|
| 2018 |
Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Medicine. PMID 29468834 DOI: 10.1002/Cam4.1356 |
0.394 |
|
| 2018 |
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, ... ... Wolchok JD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017776385. PMID 29442540 DOI: 10.1200/Jco.2017.77.6385 |
0.325 |
|
| 2018 |
Wolchok JD. Altered self: the not-so-neo-antigens. Nature Reviews. Immunology. 18: 152. PMID 29398706 DOI: 10.1038/Nri.2018.7 |
0.332 |
|
| 2018 |
Wolchok JD, Callahan MK. Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name. Cancer Journal (Sudbury, Mass.). 24: 1. PMID 29360720 DOI: 10.1097/Ppo.0000000000000305 |
0.413 |
|
| 2018 |
Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, ... ... Wolchok JD, et al. Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity. 48: 91-106.e6. PMID 29343444 DOI: 10.1016/J.Immuni.2017.12.014 |
0.346 |
|
| 2018 |
Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, ... Wolchok JD, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017751644. PMID 29341833 DOI: 10.1200/Jco.2017.75.1644 |
0.446 |
|
| 2018 |
Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Green J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, ... ... Wolchok JD, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunology Research. PMID 29339377 DOI: 10.1158/2326-6066.Cir-17-0356 |
0.472 |
|
| 2018 |
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, ... ... Wolchok J, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753384. PMID 29337640 DOI: 10.1200/Jco.2017.75.3384 |
0.401 |
|
| 2018 |
Klebanoff CA, Wolchok JD. Shared cancer neoantigens: Making private matters public. The Journal of Experimental Medicine. 215: 5-7. PMID 29269561 DOI: 10.1084/Jem.20172188 |
0.303 |
|
| 2018 |
Postow MA, Harding JJ, Hellmann MD, Gordon MS, Tsai F, O' Donoghue JA, Lewis JS, Wu AM, Le W, Korn RL, Weber W, Wolchok JD, Pandit-Taskar N. Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. Journal of Clinical Oncology. 36: e24160-e24160. DOI: 10.1200/Jco.2018.36.15_Suppl.E24160 |
0.393 |
|
| 2018 |
Gottesdiener LS, Gormally M, Armenia J, El-Jalby M, Postow MA, Callahan MK, Momtaz P, Wolchok JD, Chapman PB, Schultz N, Cohen M, Leitao MM, Hollman T, Shoushtari AN. Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E21579 |
0.359 |
|
| 2018 |
Slingluff CL, Zarour HM, Postow MA, Friedlander PA, Devoe CE, Smith K, Deacon D, Macri MJ, Ryan A, Venhaus RR, Wolchok JD. Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E15175 |
0.365 |
|
| 2018 |
Shoushtari AN, Armenia J, Arora A, Rojas-Zamalloa J, Warner AB, Derr M, Postow MA, Callahan MK, Momtaz P, Coit DG, Brady MS, Ariyan CE, Nair S, Busam KJ, Chapman PB, ... ... Wolchok JD, et al. Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma. Journal of Clinical Oncology. 36: 9561-9561. DOI: 10.1200/Jco.2018.36.15_Suppl.9561 |
0.378 |
|
| 2018 |
Warner AB, Shoushtari AN, Houghton S, Panageas K, Chapman PB, Wolchok JD, Postow MA. Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma. Journal of Clinical Oncology. 36: 9552-9552. DOI: 10.1200/Jco.2018.36.15_Suppl.9552 |
0.328 |
|
| 2018 |
Hamid O, Robert C, Daud A, Hodi FS, Hwu W, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca RS, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. Journal of Clinical Oncology. 36: 9516-9516. DOI: 10.1200/Jco.2018.36.15_Suppl.9516 |
0.324 |
|
| 2018 |
Sullivan RJ, Hong DS, Tolcher AW, Patnaik A, Shapiro G, Chmielowski B, Ribas A, Brail LH, Roberts J, Lee L, O'Connell B, Kutok JL, Mahabhashyam S, Dansky Ullmann C, Postow MA, ... Wolchok JD, et al. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. Journal of Clinical Oncology. 36: 3013-3013. DOI: 10.1200/Jco.2018.36.15_Suppl.3013 |
0.395 |
|
| 2018 |
Silk T, Choi H, Deng J, Pourpe S, Wong K, Merghoub T, Wolchok JD. Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models. Journal of Clinical Oncology. 36: 12060-12060. DOI: 10.1200/Jco.2018.36.15_Suppl.12060 |
0.34 |
|
| 2018 |
Wang W, Dai P, Yang N, Shuman S, Yan W, Merghoub T, Wolchok JD, Deng L. Abstract LB-306: Oncolytic vaccinia virus expressing immune checkpoint blockade antibody as cancer immunotherapeutics Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-306 |
0.409 |
|
| 2018 |
Cottrell TR, Stein JE, Chaft JE, Thompson ED, Rekhtman N, Anagnostou V, Smith KN, Duffield AS, Anders RA, Isbell JM, Jones DR, Cuda JD, Battafarano R, Yang SC, Illei PB, ... ... Wolchok JD, et al. Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-154 |
0.405 |
|
| 2018 |
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, ... ... Wolchok JD, et al. Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct079 |
0.421 |
|
| 2018 |
Khalil D, Campesato LF, Budhu S, Li Y, Jones C, Suek N, Liu C, Gasmi B, Giese R, Pourpe S, Merghoub T, Wolchok JD. Abstract 5009: Defined factors overcome T-cell exhaustion via abscopal effect Cancer Research. 78: 5009-5009. DOI: 10.1158/1538-7445.Am2018-5009 |
0.447 |
|
| 2018 |
Tchaicha J, McGovern K, Campesato LF, Coma S, Zhang XM, Walsh M, Cavanaugh J, Merghoub T, Wolchok J, Manfredi M. Abstract 4723: Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor Cancer Research. 78: 4723-4723. DOI: 10.1158/1538-7445.Am2018-4723 |
0.453 |
|
| 2018 |
Schad S, Hirschhorn-Cymerman D, Budhu S, Zhong H, Yang X, Shan J, King S, Merghoub T, Wolchok J. Abstract 3568: Phosphatidylserine targeting antibody enhances antitumor activity of CAR T cells in mouse melanoma Cancer Research. 78: 3568-3568. DOI: 10.1158/1538-7445.Am2018-3568 |
0.467 |
|
| 2018 |
Giese R, Budhu S, Barker C, Gupta A, King S, Shan J, Wolchok J, Merghoub T. Abstract 2767: Phosphatidylserine targeting and radiation improves survival in a mouse tumor model resistant to checkpoint blockade Cancer Research. 78: 2767-2767. DOI: 10.1158/1538-7445.Am2018-2767 |
0.438 |
|
| 2018 |
Warner AB, Hirschhorn D, Cohen A, Liu C, Newman W, Sirard C, Wolchok J, Merghoub T. Abstract 1699: Treatment with agonist anti-GITR antibody after chemotherapy enhances tumor immunity Cancer Research. 78: 1699-1699. DOI: 10.1158/1538-7445.Am2018-1699 |
0.459 |
|
| 2018 |
Wang W, Dai P, Yang N, Wang Y, Shuman S, Merghoub T, Wolchok J, Deng L. 020 The combination of intratumoral delivery of inactivated modified vaccinia virus Ankara with systemic delivery of immune checkpoint blockade enhances antitumor immunity Journal of Investigative Dermatology. 138: S4. DOI: 10.1016/J.Jid.2018.03.024 |
0.32 |
|
| 2017 |
Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, Singh-Kandah S, Dickson MA, D'Angelo SP, Wolchok JD, Young JW. Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. Oncoimmunology. 7: e1372081. PMID 29296525 DOI: 10.1080/2162402X.2017.1372081 |
0.338 |
|
| 2017 |
Momtaz P, Harding JJ, Ariyan C, Coit DG, Merghoub T, Gasmi B, You D, Viale A, Panageas KS, Samoila A, Postow MA, Wolchok JD, Chapman PB. Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 8: 105000-105010. PMID 29285228 DOI: 10.18632/Oncotarget.21072 |
0.326 |
|
| 2017 |
Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, ... ... Wolchok JD, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. PMID 29132146 DOI: 10.1038/Nature24462 |
0.363 |
|
| 2017 |
Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. PMID 29132144 DOI: 10.1038/Nature24473 |
0.421 |
|
| 2017 |
Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017722850. PMID 29040030 DOI: 10.1200/Jco.2017.72.2850 |
0.378 |
|
| 2017 |
Anderson ES, Postow MA, Wolchok JD, Young RJ, Ballangrud Å, Chan TA, Yamada Y, Beal K. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. Journal For Immunotherapy of Cancer. 5: 76. PMID 29037215 DOI: 10.1186/S40425-017-0282-X |
0.348 |
|
| 2017 |
Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, ... ... Wolchok JD, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016721167. PMID 28915085 DOI: 10.1200/Jco.2016.72.1167 |
0.426 |
|
| 2017 |
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine. PMID 28889792 DOI: 10.1056/Nejmoa1709684 |
0.344 |
|
| 2017 |
Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, Zhong H, Houghton AN, Silverstein SC, Merghoub T, Wolchok JD. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science Signaling. 10. PMID 28851824 DOI: 10.1126/Scisignal.Aak9702 |
0.419 |
|
| 2017 |
Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell. 170: 927-938.e20. PMID 28841418 DOI: 10.1016/J.Cell.2017.07.025 |
0.458 |
|
| 2017 |
Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017732289. PMID 28841387 DOI: 10.1200/Jco.2017.73.2289 |
0.358 |
|
| 2017 |
Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. Jama Oncology. PMID 28817755 DOI: 10.1001/Jamaoncol.2017.2391 |
0.384 |
|
| 2017 |
Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science Immunology. 2. PMID 28763795 DOI: 10.1126/Sciimmunol.Aal1713 |
0.419 |
|
| 2017 |
Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. Jama Oncology. PMID 28662232 DOI: 10.1001/Jamaoncol.2017.1588 |
0.411 |
|
| 2017 |
Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, et al. Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer (Oxford, England : 1990). 82: 80-91. PMID 28651159 DOI: 10.1016/J.Ejca.2017.05.031 |
0.414 |
|
| 2017 |
Merghoub T, Wolchok JD. Curbing Tregs’ (Lack of) Enthusiasm Cell. 169: 981-982. PMID 28575677 DOI: 10.1016/J.Cell.2017.05.027 |
0.386 |
|
| 2017 |
Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. PMID 28514453 DOI: 10.1038/Nature22367 |
0.366 |
|
| 2017 |
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, ... ... Wolchok JD, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. PMID 28397821 DOI: 10.1038/Nature22079 |
0.433 |
|
| 2017 |
Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, Postow MA, Ariyan C. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. Ebiomedicine. PMID 28356222 DOI: 10.1016/J.Ebiom.2017.03.029 |
0.343 |
|
| 2017 |
Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, ... ... Wolchok J, et al. Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 28247127 DOI: 10.1007/S00520-017-3621-Z |
0.364 |
|
| 2017 |
Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. Journal For Immunotherapy of Cancer. 5: 16. PMID 28239469 DOI: 10.1186/S40425-017-0218-5 |
0.395 |
|
| 2017 |
Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications. 8: 14340. PMID 28194010 DOI: 10.1038/Ncomms14340 |
0.369 |
|
| 2017 |
Ricca J, Turkekul M, Barlas A, Yarilin D, Fujisawa S, Fan N, Brendel M, Zamarin D, Wolchok JD, Manova-Todorova K. Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods in Molecular Biology (Clifton, N.J.). 1554: 253-262. PMID 28185198 DOI: 10.1007/978-1-4939-6759-9_18 |
0.321 |
|
| 2017 |
Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, ... ... Wolchok JD, et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer (Oxford, England : 1990). 73: 61-70. PMID 28167454 DOI: 10.1016/J.Ejca.2016.12.011 |
0.374 |
|
| 2017 |
Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. The Lancet. Oncology. PMID 28162999 DOI: 10.1016/S1470-2045(17)30015-3 |
0.328 |
|
| 2017 |
Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nature Reviews. Endocrinology. PMID 28106152 DOI: 10.1038/Nrendo.2016.205 |
0.431 |
|
| 2017 |
D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH, Mohr P, Marquez-Rodas I, Charles J, ... ... Wolchok JD, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 226-235. PMID 28056206 DOI: 10.1200/Jco.2016.67.9258 |
0.387 |
|
| 2017 |
Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, Callahan MK, Wolchok JD, Chapman PB, Hellmann MD, Postow MA. Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 109. PMID 28040701 DOI: 10.1093/Jnci/Djw260 |
0.369 |
|
| 2017 |
Friedman CF, Wolchok JD, Postow MA, Shoushtari AN, Callahan MK, Momtaz P, Chapman PB. Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors. Journal of Clinical Oncology. 35: 100-100. DOI: 10.1200/Jco.2017.35.7_Suppl.100 |
0.378 |
|
| 2017 |
Callahan MK, Kania BE, Iyer G, Clement JM, Funt S, McCoy AS, Hettich G, Ziv E, Bluth MJ, Wong P, Wolchok JD, Bajorin DF, Rosenberg JE. Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC). Journal of Clinical Oncology. 35: 384-384. DOI: 10.1200/Jco.2017.35.6_Suppl.384 |
0.392 |
|
| 2017 |
Weber JS, Larkin JMG, Schadendorf D, Wolchok JD, Wagstaff J, Dummer R, Hogg D, Guidoboni M, Sosman JA, Chmielowski B, Gerritsen W, Bhore R, Walker D, Gonzalez R. Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). Journal of Clinical Oncology. 35: 9523-9523. DOI: 10.1200/Jco.2017.35.15_Suppl.9523 |
0.334 |
|
| 2017 |
Teo M, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Solit DB, Funt S, Wolchok JD, Iyer G, Charen AS, et al. DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 35: 4509-4509. DOI: 10.1200/Jco.2017.35.15_Suppl.4509 |
0.335 |
|
| 2017 |
Callahan MK, Odunsi K, Sznol M, Nemunaitis JJ, Ott PA, Dillon PM, Park AJ, Schwarzenberger P, Ricciardi T, Macri MJ, Ryan A, Venhaus RR, Wolchok JD. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. Journal of Clinical Oncology. 35: 3069-3069. DOI: 10.1200/Jco.2017.35.15_Suppl.3069 |
0.378 |
|
| 2017 |
Jiménez-Sánchez A, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Aghajanian C, Wolchok JD, Merghoub T, Sala E, Snyder A, et al. Abstract B09: Heterogeneous fates of metastatic lesions linked to immune escape in an ovarian cancer patient Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B09 |
0.468 |
|
| 2017 |
Tolcher A, Hong D, Sullivan R, Mier J, Shapiro G, Chmielowski B, Ribas A, Postow M, Pearlberg J, Brail L, Lee L, Ullmann CAD, Wolchok JD. Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct089 |
0.48 |
|
| 2017 |
Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Haanen J, Maio M, McArthur G, ... ... Wolchok JD, et al. Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct075 |
0.381 |
|
| 2017 |
Ribas A, Martín-Algarra S, Bhatia S, Hwu W, Slingluff CL, Sharfman WH, Hodi FS, Urba WJ, Luke JJ, Haanen JB, Callahan MK, Wolchok JD, Chasalow SD, Ross-Macdonald P, Young TC, et al. Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038 Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct073 |
0.423 |
|
| 2017 |
Zappasodi R, Li Y, Abu-Akeel M, Qi J, Wong P, Sirard C, Postow M, Schaer DA, Newman W, Koon H, Velcheti V, Callahan MK, Wolchok JD, Merghoub T. Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct018 |
0.471 |
|
| 2017 |
Ghamsari L, Flano E, Jacques J, Liu B, Yan Z, Alami A, Kelley C, Zhang T, Havel J, Makarov V, Merghoub T, Wolchok JD, Hellman M, Carroll P, Chan T, et al. Abstract 632: Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a non-small cell lung cancer patient Cancer Research. 77: 632-632. DOI: 10.1158/1538-7445.Am2017-632 |
0.443 |
|
| 2017 |
Budhu S, Henau OD, Zappasodi R, Giese R, Campesato LF, Barker C, Freimark B, Hutchins J, Wolchok JD, Merghoub T. Abstract 574: Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma Cancer Research. 77: 574-574. DOI: 10.1158/1538-7445.Am2017-574 |
0.462 |
|
| 2017 |
McArthur H, Beal K, Halpenny D, Henrich M, Modi S, Patil S, Young R, Kaley T, Merghoub T, Barker C, Wong P, Hamilton N, Hudis C, Wolchok J, Norton L. Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM) Cancer Research. 77: 4705-4705. DOI: 10.1158/1538-7445.Am2017-4705 |
0.339 |
|
| 2017 |
Hirschhorn-Cymerman D, Schad SS, Budhu S, Hong Z, Yang X, Jeff HT, Freimark BD, Gray MJ, Wolchok J, Merghoub T. Abstract 1651: Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model Cancer Research. 77: 1651-1651. DOI: 10.1158/1538-7445.Am2017-1651 |
0.466 |
|
| 2017 |
Wolchok JD, Wherry EJ. Webinar | Deciphering cancer: Modulating immunoregulatory pathways to treat tumors Science. 355: 210-210. DOI: 10.1126/Science.355.6321.210-B |
0.436 |
|
| 2017 |
Grob J, Schadendorf D, Wagstaff J, Márquez-Rodas I, Lebbé C, Ascierto PA, Hodi FS, Grossmann K, Hassel JC, Walker D, Bhore R, Larkin J, Wolchok JD. 1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx377.009 |
0.346 |
|
| 2017 |
Robert C, Larkin J, Ascierto PA, Long GV, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob J, Grossmann K, Wagstaff J, Chesney J, Hogg D, Bechter O, Márquez-Rodas I, ... ... Wolchok JD, et al. 1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx377 |
0.344 |
|
| 2016 |
Remark R, Merghoub T, Grabe N, Litjens G, Damotte D, Wolchok JD, Merad M, Gnjatic S. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology. 1: aaf6925. PMID 28783673 DOI: 10.1126/Sciimmunol.Aaf6925 |
0.371 |
|
| 2016 |
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD. Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27998967 DOI: 10.1093/annonc/mdw640 |
0.323 |
|
| 2016 |
Shia J, Schultz N, Kuk D, Vakiani E, Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR, Wolchok JD, Boland CR, Gönen M, Klimstra DS. Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27982025 DOI: 10.1038/Modpathol.2016.198 |
0.36 |
|
| 2016 |
Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4102-4109. PMID 27863197 DOI: 10.1200/Jco.2016.67.2477 |
0.406 |
|
| 2016 |
De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, ... ... Wolchok JD, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. PMID 27828943 DOI: 10.1038/Nature20554 |
0.422 |
|
| 2016 |
Snyder A, Wolchok JD. Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next? Cancer Discovery. 6: 1210-1211. PMID 27807100 DOI: 10.1158/2159-8290.Cd-16-1056 |
0.363 |
|
| 2016 |
Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27797971 DOI: 10.1158/1078-0432.Ccr-16-1241 |
0.323 |
|
| 2016 |
Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, et al. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Research. PMID 27792058 DOI: 10.1097/Cmr.0000000000000306 |
0.354 |
|
| 2016 |
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. The New England Journal of Medicine. PMID 27717298 DOI: 10.1056/Nejmoa1611299 |
0.351 |
|
| 2016 |
Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, et al. Kinase regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research. PMID 27680026 DOI: 10.1158/2326-6066.Cir-16-0177 |
0.368 |
|
| 2016 |
Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, ... ... Wolchok JD, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet. Oncology. PMID 27622997 DOI: 10.1016/S1470-2045(16)30366-7 |
0.4 |
|
| 2016 |
Holmgaard RB, Brachfeld A, Gasmi B, Jones DR, Mattar M, Doman T, Murphy M, Schaer D, Wolchok JD, Merghoub T. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology. 5: e1151595. PMID 27622016 DOI: 10.1080/2162402X.2016.1151595 |
0.365 |
|
| 2016 |
Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon SB, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, ... ... Wolchok JD, et al. Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunology Research. PMID 27587469 DOI: 10.1158/2326-6066.Cir-16-0013 |
0.412 |
|
| 2016 |
McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, ... ... Wolchok JD, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27566765 DOI: 10.1158/1078-0432.Ccr-16-0190 |
0.328 |
|
| 2016 |
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, ... ... Wolchok JD, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. PMID 27533633 DOI: 10.1002/Cncr.30259 |
0.359 |
|
| 2016 |
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, ... ... Wolchok J, ... ... Wolchok JD, et al. Melanoma and Immunotherapy Bridge 2015 : Naples, Italy. 1-5 December 2015 Journal of Translational Medicine. 14: 65-65. PMID 27461275 DOI: 10.1186/S12967-016-0791-2 |
0.325 |
|
| 2016 |
Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, ... ... Wolchok JD, et al. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer (Oxford, England : 1990). 64: 116-126. PMID 27400322 DOI: 10.1016/J.Ejca.2016.06.001 |
0.379 |
|
| 2016 |
Hellmann M, Rizvi N, Wolchok JD, Chan TA. Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Molecular & Cellular Oncology. 3: e1048929. PMID 27308563 DOI: 10.1080/23723556.2015.1048929 |
0.375 |
|
| 2016 |
Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. The Oncologist. PMID 27286787 DOI: 10.1634/Theoncologist.2015-0522 |
0.329 |
|
| 2016 |
Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney International. PMID 27282937 DOI: 10.1016/J.Kint.2016.04.008 |
0.35 |
|
| 2016 |
Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27269940 DOI: 10.1200/Jco.2015.65.5142 |
0.422 |
|
| 2016 |
Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee C. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. The Journal of Experimental Medicine. PMID 27242164 DOI: 10.1084/Jem.20152021 |
0.436 |
|
| 2016 |
Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, ... ... Wolchok JD, et al. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European Journal of Cancer (Oxford, England : 1990). PMID 27237360 DOI: 10.1016/J.Ejca.2016.03.082 |
0.323 |
|
| 2016 |
Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. Ebiomedicine. 6: 50-8. PMID 27211548 DOI: 10.1016/J.Ebiom.2016.02.024 |
0.406 |
|
| 2016 |
Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 44: 1069-78. PMID 27192570 DOI: 10.1016/J.Immuni.2016.04.023 |
0.441 |
|
| 2016 |
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, ... ... Wolchok JD, et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 5487-5496. PMID 27185375 DOI: 10.1158/1078-0432.Ccr-16-0127 |
0.352 |
|
| 2016 |
Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27169993 DOI: 10.1158/1078-0432.Ccr-16-0249 |
0.355 |
|
| 2016 |
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Jama. 315: 1600-9. PMID 27092830 DOI: 10.1001/Jama.2016.4059 |
0.415 |
|
| 2016 |
Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Experimental Dermatology. 25: 553-554. PMID 27061281 DOI: 10.1111/Exd.13030 |
0.352 |
|
| 2016 |
Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European Journal of Cancer (Oxford, England : 1990). 60: 12-25. PMID 27043866 DOI: 10.1016/J.Ejca.2016.02.010 |
0.36 |
|
| 2016 |
Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, ... ... Wolchok J, et al. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. Journal For Immunotherapy of Cancer. 4: 15. PMID 26981245 DOI: 10.1186/S40425-016-0118-0 |
0.412 |
|
| 2016 |
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews. Clinical Oncology. PMID 26977780 DOI: 10.1038/Nrclinonc.2016.25 |
0.433 |
|
| 2016 |
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, ... ... Wolchok JD, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26951310 DOI: 10.1200/Jco.2015.64.0391 |
0.408 |
|
| 2016 |
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, ... ... Wolchok JD, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). PMID 26940869 DOI: 10.1126/Science.Aaf1490 |
0.491 |
|
| 2016 |
Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine. 8: 328rv4. PMID 26936508 DOI: 10.1126/Scitranslmed.Aad7118 |
0.369 |
|
| 2016 |
Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, ... ... Wolchok JD, et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunology Research. PMID 26928461 DOI: 10.1158/2326-6066.Cir-15-0123 |
0.42 |
|
| 2016 |
Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL, Sallusto F, ... ... Wolchok J, et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. The Journal of Clinical Investigation. PMID 26854930 DOI: 10.1172/Jci80071 |
0.395 |
|
| 2016 |
Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature Communications. 7: 10391. PMID 26837003 DOI: 10.1038/Ncomms10391 |
0.334 |
|
| 2016 |
Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Research. PMID 26795274 DOI: 10.1097/Cmr.0000000000000234 |
0.392 |
|
| 2016 |
Malandro N, Budhu S, Kuhn NF, Liu C, Murphy JT, Cortez C, Zhong H, Yang X, Rizzuto G, Altan-Bonnet G, Merghoub T, Wolchok JD. Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity. 44: 179-193. PMID 26789923 DOI: 10.1016/J.Immuni.2015.12.018 |
0.687 |
|
| 2016 |
Martens A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, ... ... Wolchok JD, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26787752 DOI: 10.1158/1078-0432.Ccr-15-2412 |
0.399 |
|
| 2016 |
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Reply to A. Indini et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786917 DOI: 10.1200/Jco.2015.65.7007 |
0.363 |
|
| 2016 |
Tolcher AW, Hong DS, Sullivan RJ, Mier JW, Shapiro G, Pearlberg J, Brail LH, Kharidia J, Han L, Ullmann CD, Stern HM, Wolchok JD. IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3111 |
0.436 |
|
| 2016 |
Plitas G, Wu K, Carlson J, Cimaglia N, Morrow M, Rudensky AY, Wolchok JD. Phase I/II study of mogamulizumab, an anti-CCR4 antibody targeting regulatory T cells in advanced cancer patients. Journal of Clinical Oncology. 34: TPS3098-TPS3098. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3098 |
0.418 |
|
| 2016 |
Cassidy MR, Wolchok R, Zheng J, Panageas K, Wolchok JD, Coit DG, Postow MA, Ariyan CE. Neutrophil to lymphocyte ratio to predict outcome during ipilimumab treatment. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E21008 |
0.35 |
|
| 2016 |
Forde PM, Smith K, Chaft JE, Hellmann MD, Merghoub T, Wolchok JD, Yang SC, Battafarano RJ, Gabrielson E, Georgiades C, Verde F, Rosner GL, Anagnostou V, Velculescu VE, Topalian SL, et al. Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. Journal of Clinical Oncology. 34: e20005-e20005. DOI: 10.1200/Jco.2016.34.15_Suppl.E20005 |
0.363 |
|
| 2016 |
Shoushtari AN, Navid-Azarbaijani P, Friedman CF, Panageas K, Postow MA, Callahan MK, Momtaz P, Campbell SC, Shames Y, Prempeh-Keteku NA, Nwaedozie K, Wolchok JD, Chapman PB. Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP). Journal of Clinical Oncology. 34: 9554-9554. DOI: 10.1200/Jco.2016.34.15_Suppl.9554 |
0.335 |
|
| 2016 |
Friedman CF, Navid-Azarbaijani P, Shoushtari AN, Campbell SC, Callahan MK, Momtaz P, Prempeh-Keteku NA, Postow MA, Shames Y, Wolchok JD, Chapman PB. Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP). Journal of Clinical Oncology. 34: 9519-9519. DOI: 10.1200/Jco.2016.34.15_Suppl.9519 |
0.326 |
|
| 2016 |
Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala S, Shaheen MF, Ernstoff MS, Minor DR, Salama AK, ... ... Wolchok JD, et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). Journal of Clinical Oncology. 34: 9518-9518. DOI: 10.1200/Jco.2016.34.15_Suppl.9518 |
0.35 |
|
| 2016 |
Munhoz RR, Shoushtari AN, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, ... ... Wolchok JD, et al. Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. Journal of Clinical Oncology. 34: 9516-9516. DOI: 10.1200/Jco.2016.34.15_Suppl.9516 |
0.395 |
|
| 2016 |
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Haanen JBAG, Maio M, McArthur GA, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Journal of Clinical Oncology. 34: 9505-9505. DOI: 10.1200/Jco.2016.34.15_Suppl.9505 |
0.383 |
|
| 2016 |
Manders P, Joshua AM, Gangadhar TC, Joseph R, Dronca R, Patnaik A, Zarour H, Hersey P, Li XN, Diede SJ, Ebbinghaus S, Hodi FS, Kefford R, Robert C, Ribas A, ... ... Wolchok JD, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Journal of Clinical Oncology. 12: 47-48. DOI: 10.1200/Jco.2016.34.15_Suppl.9503 |
0.379 |
|
| 2016 |
Postow MA, Kuk D, Adamow M, Carrera C, Wong P, Curran MA, Friedman CF, Momtaz P, Shoushtari AN, Wolchok JD, Chapman PB, Callahan MK. Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone. Journal of Clinical Oncology. 34: 3073-3073. DOI: 10.1200/Jco.2016.34.15_Suppl.3073 |
0.364 |
|
| 2016 |
Koon HB, Shepard DR, Merghoub T, Schaer DA, Sirard CA, Wolchok JD. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. Journal of Clinical Oncology. 34: 3017-3017. DOI: 10.1200/Jco.2016.34.15_Suppl.3017 |
0.444 |
|
| 2016 |
Philip M, Fairchild L, Sun L, Viale A, Merghoub T, Wolchok JD, Leslie CS, Schietinger A. Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer Blood. 128: 861-861. DOI: 10.1182/Blood.V128.22.861.861 |
0.399 |
|
| 2016 |
Wolchok JD. Abstract IA10: Combination checkpoint blockade Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia10 |
0.469 |
|
| 2016 |
Remark R, Merghoub T, Damotte D, Wolchok JD, Merad M, Gnjatic S. Abstract B109: In-depth tissue analysis using multiplexed immunohistochemical consecutive staining on single slide Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B109 |
0.421 |
|
| 2016 |
Dai P, Wang W, Serna-Tamayo C, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L. Abstract B031: Heat-inactivated modified vaccinia virus ankara induces type I IFN and antitumor immunity via the cytosolic DNA-sensing pathway Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B031 |
0.423 |
|
| 2016 |
Philip M, Fairchild L, Sun L, Viale A, Camara S, Horste E, Merghoub T, Wolchok JD, Leslie CS, Schietinger A. Abstract PR09: Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr09 |
0.412 |
|
| 2016 |
Zappasodi R, Ghosh A, Serganova I, Cohen I, Senbabaoglu Y, Shindo M, Mane MM, Leftin A, Ackerstaff E, Koutcher JA, Wolchok JD, Blasberg RG, Merghoub T. Abstract PR06: Overcoming intratumor T-cell exclusion by modulation of lactate metabolism to improve immune checkpoint therapies in aggressive breast cancer Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr06 |
0.492 |
|
| 2016 |
Huang A, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Adamow M, Kuk D, Panangeas K, Carerra C, Wong P, Quagliarello F, Pauken KE, ... ... Wolchok JD, et al. Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr05 |
0.488 |
|
| 2016 |
Tolcher A, Hong D, Sullivan R, Mier J, Shapiro G, Pearlberg J, Brail L, Kharidia J, Han L, Ullmann CD, Stern HM, Wolchok JD. Abstract B070: IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B070 |
0.443 |
|
| 2016 |
Khalil DN, Campesato LF, Li Y, Merghoub T, Wolchok JD. Abstract B059: Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to regress tumors systemically Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B059 |
0.44 |
|
| 2016 |
Rausch M, Tchaicha J, Tibbitts T, Henau OD, Sharma S, Pink M, Gladstone J, Proctor J, Douglas M, Stern H, Merghoub T, Wolchok J, McGovern K, Kutok J, Winkler D. Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B032 |
0.475 |
|
| 2016 |
Wang W, Dai P, Yang N, Shuman S, Merghoub T, Wolchok JD, Deng L. Abstract A007: Intratumoral delivery of inactivated vaccinia virus is more efficacious than live oncolytic vaccinia virus in murine bilateral tumor implantation models Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A007 |
0.361 |
|
| 2016 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Wolchok J, Zahnow CA, Mergoub T, et al. Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B32 |
0.416 |
|
| 2016 |
Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D, Linette G, Meyer N, Giguere J, Agarwala S, Shaheen M, Ernstoff M, Minor D, Salama A, Taylor M, ... ... Wolchok J, et al. Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct002 |
0.387 |
|
| 2016 |
Henau OD, Merghoub T, Winkler D, Sharma S, Pink M, Tchaicha J, Rausch M, Proctor J, Kosmider N, Soglia J, Palombella V, Kutok JL, Wolchok JD, McGovern K. Abstract 554: Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models Cancer Research. 76: 554-554. DOI: 10.1158/1538-7445.Am2016-554 |
0.466 |
|
| 2016 |
Drouin EE, Gonzalez A, Tang H, Savitsky D, Gombos R, Waight J, Duckless B, Schuster A, Wang L, Lin S, Mundt C, Ritter G, Merghoub T, Draleau K, Wolchok J, et al. Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies Cancer Research. 76: 5005-5005. DOI: 10.1158/1538-7445.Am2016-5005 |
0.421 |
|
| 2016 |
Gonzalez AM, Breous E, Manrique ML, Savitsky D, Waight J, Gombos R, Liu Y, Lin S, Leger O, Seibert V, Tsuji T, Merghoub T, Budha S, Zappasodi R, Ritter G, ... Wolchok J, et al. Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR Cancer Research. 76: 3220-3220. DOI: 10.1158/1538-7445.Am2016-3220 |
0.439 |
|
| 2016 |
Gonzalez AM, Manrique ML, Breous E, Savitsky D, Waight J, Gombos R, Liu Y, Lin S, Merghoub T, Hirschhorn-Cymerman D, Ritter G, Wolchok J, Scherle P, Hollis G, Huber R, et al. Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells Cancer Research. 76: 3204-3204. DOI: 10.1158/1538-7445.Am2016-3204 |
0.457 |
|
| 2016 |
Zuleger CL, Kang C, Ranheim EA, Kurzman I, Macklin MD, Newton MA, Vail DM, Wolchok JD, Eriksson E, Albertini MR. Abstract 2366: Pilot study of DNA microseeding to activate immune rejection of canine melanoma Cancer Research. 76: 2366-2366. DOI: 10.1158/1538-7445.Am2016-2366 |
0.327 |
|
| 2016 |
Eggermont AMM, Chiarion-Sileni V, Grob J, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Taitt C, et al. melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw435.35 |
0.306 |
|
| 2016 |
Sznol M, Ferrucci PF, Hogg D, Atkins M, Wolter P, Guidoboni M, Lebbe C, Kirkwood J, Schachter J, Daniels G, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, ... ... Wolchok J, et al. Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw379.18 |
0.332 |
|
| 2016 |
Segal N, Infante J, Sanborn R, Gibney G, Lawrence D, Rizvi N, Leidner R, Gajewski T, Bertino E, Sharfman W, Cooley S, Topalian S, Urba W, Wolchok J, Gu X, et al. Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors Annals of Oncology. 27: vi372. DOI: 10.1093/Annonc/Mdw378.40 |
0.366 |
|
| 2015 |
Snyder A, Pamer E, Wolchok J. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy? Science (New York, N.Y.). 350: 1031-2. PMID 26612936 DOI: 10.1126/Science.Aad7706 |
0.317 |
|
| 2015 |
Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Science Advances. 1: e1500845. PMID 26601142 DOI: 10.1126/Sciadv.1500845 |
0.399 |
|
| 2015 |
Merchant M, Wright M, Baird K, Wexler L, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL. Phase 1 Clinical Trial of Ipilimumab In Pediatric Patients With Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26534966 DOI: 10.1158/1078-0432.Ccr-15-0491 |
0.446 |
|
| 2015 |
Snyder A, Makarov V, Hellmann M, Rizvi N, Merghoub T, Wolchok JD, Chan TA. Genetics and immunology: reinvigorated. Oncoimmunology. 4: e1029705. PMID 26451299 DOI: 10.1080/2162402X.2015.1029705 |
0.414 |
|
| 2015 |
Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. PMID 26411680 DOI: 10.1016/J.Celrep.2015.08.077 |
0.409 |
|
| 2015 |
Snyder A, Zamarin D, Wolchok JD. Immunotherapy of Melanoma. Progress in Tumor Research. 42: 22-9. PMID 26376963 DOI: 10.1159/000436998 |
0.314 |
|
| 2015 |
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26371282 DOI: 10.1093/Annonc/Mdv383 |
0.372 |
|
| 2015 |
Callahan MK, Wolchok JD. Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in Oncology. 42: 573-86. PMID 26320062 DOI: 10.1053/J.Seminoncol.2015.05.008 |
0.427 |
|
| 2015 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 162: 974-86. PMID 26317466 DOI: 10.1016/J.Cell.2015.07.011 |
0.399 |
|
| 2015 |
Wolchok JD. PD-1 Blockers Cell. 162: 937-937. PMID 26317459 DOI: 10.1016/J.Cell.2015.07.045 |
0.415 |
|
| 2015 |
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26282644 DOI: 10.1200/Jco.2015.60.8448 |
0.413 |
|
| 2015 |
Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in Cancer Research. 128: 1-68. PMID 26216629 DOI: 10.1016/Bs.Acr.2015.04.010 |
0.473 |
|
| 2015 |
Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Jama Oncology. 1: 433-40. PMID 26181250 DOI: 10.1001/Jamaoncol.2015.1184 |
0.393 |
|
| 2015 |
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, ... ... Wolchok JD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology. PMID 26115796 DOI: 10.1016/S1470-2045(15)00083-2 |
0.377 |
|
| 2015 |
Postow MA, Manuel M, Wong P, Yuan J, Dong Z, Liu C, Perez S, Tanneau I, Noel M, Courtier A, Pasqual N, Wolchok JD. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal For Immunotherapy of Cancer. 3: 23. PMID 26085931 DOI: 10.1186/S40425-015-0070-4 |
0.38 |
|
| 2015 |
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, ... ... Wolchok JD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine. 373: 23-34. PMID 26027431 DOI: 10.1056/Nejmoa1504030 |
0.361 |
|
| 2015 |
Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. The Oncologist. 20: 648-52. PMID 25964307 DOI: 10.1634/Theoncologist.2014-0468 |
0.336 |
|
| 2015 |
Papaspyridonos M, Matei I, Huang Y, do Rosario Andre M, Brazier-Mitouart H, Waite JC, Chan AS, Kalter J, Ramos I, Wu Q, Williams C, Wolchok JD, Chapman PB, Peinado H, Anandasabapathy N, et al. Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nature Communications. 6: 6840. PMID 25924227 DOI: 10.1038/Ncomms7840 |
0.374 |
|
| 2015 |
Chapman PB, D'Angelo SP, Wolchok JD. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. The New England Journal of Medicine. 372: 2073-4. PMID 25891305 DOI: 10.1056/Nejmc1501894 |
0.343 |
|
| 2015 |
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, ... ... Wolchok JD, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England Journal of Medicine. 372: 2006-17. PMID 25891304 DOI: 10.1056/Nejmoa1414428 |
0.403 |
|
| 2015 |
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 16: 522-30. PMID 25840693 DOI: 10.1016/S1470-2045(15)70122-1 |
0.363 |
|
| 2015 |
Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine. 7: 280sr1. PMID 25810313 DOI: 10.1126/Scitranslmed.3010274 |
0.446 |
|
| 2015 |
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, ... ... Wolchok JD, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 348: 124-8. PMID 25765070 DOI: 10.1126/Science.Aaa1348 |
0.451 |
|
| 2015 |
Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. International Journal of Radiation Oncology, Biology, Physics. 92: 368-75. PMID 25754629 DOI: 10.1016/J.Ijrobp.2015.01.004 |
0.387 |
|
| 2015 |
Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1191-6. PMID 25713437 DOI: 10.1200/Jco.2014.56.6018 |
0.351 |
|
| 2015 |
Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, et al. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2289-96. PMID 25695690 DOI: 10.1158/1078-0432.Ccr-14-1630 |
0.316 |
|
| 2015 |
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1889-94. PMID 25667295 DOI: 10.1200/Jco.2014.56.2736 |
0.331 |
|
| 2015 |
Shahabi V, Postow MA, Tuck D, Wolchok JD. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. American Journal of Clinical Oncology. 38: 90-97. PMID 25616204 DOI: 10.1097/Coc.0B013E3182868Ec8 |
0.45 |
|
| 2015 |
Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1974-82. PMID 25605845 DOI: 10.1200/Jco.2014.59.4358 |
0.367 |
|
| 2015 |
Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M, Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, Saenger Y. Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunology Research. 3: 296-304. PMID 25600438 DOI: 10.1158/2326-6066.Cir-14-0120 |
0.426 |
|
| 2015 |
Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 25: 208-24. PMID 25582080 DOI: 10.1038/Cr.2015.3 |
0.333 |
|
| 2015 |
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. Journal of Immunology (Baltimore, Md. : 1950). 194: 950-9. PMID 25539810 DOI: 10.4049/Jimmunol.1401686 |
0.416 |
|
| 2015 |
Gerber NK, Young RJ, Barker CA, Wolchok JD, Chan TA, Yamada Y, Friguglietti L, Beal K. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. Journal of Neuro-Oncology. 121: 159-65. PMID 25273687 DOI: 10.1007/S11060-014-1617-9 |
0.366 |
|
| 2015 |
Ahuja A, Nathanson T, Rubinsteyn A, Snyder A, Hellman M, Chan T, Merghoub T, Wolchok J, Hammerbacher J. Neoantigen homology and predicting response to immune checkpoint blockade in cancer F1000research. 4. DOI: 10.7490/F1000Research.1110758.1 |
0.346 |
|
| 2015 |
Ott PA, Callahan MK, Odunsi K, Park AJ, Pan LS, Venhaus RR, Karakunnel JJ, Hodi FS, Wolchok JD. A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps3099 |
0.424 |
|
| 2015 |
Munhoz RR, Merghoub T, Emerson RO, Callahan MK, Wolchok JD, Postow MA. Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab. Journal of Clinical Oncology. 33: 9075-9075. DOI: 10.1200/Jco.2015.33.15_Suppl.9075 |
0.432 |
|
| 2015 |
Robert C, Joshua AM, Kefford R, Joseph RW, Wolchok JD, Hodi FS, Hamid O, Weber JS, Gangadhar TC, Dronca RS, Patnaik A, Zarour HM, Hwu W, Hersey P, Daud A, et al. Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. Journal of Clinical Oncology. 33: 9050-9050. DOI: 10.1200/Jco.2015.33.15_Suppl.9050 |
0.304 |
|
| 2015 |
Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. Journal of Clinical Oncology. 33: 9005-9005. DOI: 10.1200/Jco.2015.33.15_Suppl.9005 |
0.358 |
|
| 2015 |
Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen MF, Ernstoff MS, Minor DR, Salama A, ... ... Wolchok JD, et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. Journal of Clinical Oncology. 33: 9004-9004. DOI: 10.1200/Jco.2015.33.15_Suppl.9004 |
0.385 |
|
| 2015 |
Naidoo J, Steele K, Sima CS, Yuan J, Robbins PB, Moreira AL, Pietanza MC, Wolchok JD, Riely GJ, Rizvi NA. Defining the immunologic phenotype of thymic epithelial tumors. Journal of Clinical Oncology. 33: 7516-7516. DOI: 10.1200/Jco.2015.33.15_Suppl.7516 |
0.459 |
|
| 2015 |
Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Zarour HM, Kefford R, Loboda A, Albright A, Kang SP, Ebbinghaus S, Yearley J, Murphy E, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Journal of Clinical Oncology. 33: 3001-3001. DOI: 10.1200/Jco.2015.33.15_Suppl.3001 |
0.379 |
|
| 2015 |
Wolchok JD, Hamid O, Ribas A, Robert C, Kefford R, Hwu W, Weber JS, Joshua AM, Gangadhar TC, Dronca RS, Daud A, Patnaik A, Joseph RW, Zarour HM, Li XN, et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. Journal of Clinical Oncology. 33: 3000-3000. DOI: 10.1200/Jco.2015.33.15_Suppl.3000 |
0.405 |
|
| 2015 |
Bartell H, Wolchok J, Hodi FS, Liu H, Wojtaszek C, Weber J. Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI) Journal For Immunotherapy of Cancer. 3: 384. DOI: 10.1186/2051-1426-3-S2-P384 |
0.377 |
|
| 2015 |
Khalil D, Merghoub T, Wolchok J. Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy Journal For Immunotherapy of Cancer. 3: 361. DOI: 10.1186/2051-1426-3-S2-P361 |
0.49 |
|
| 2015 |
Sharma M, Shinde R, McGaha T, Huang L, Holmgaard R, Wolchok J, Mautino M, Celis E, Sharpe A, Francisco L, Powell J, Yagita H, Mellor A, Blazar B, Munn D. The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells Journal For Immunotherapy of Cancer. 3: O19. DOI: 10.1186/2051-1426-3-S2-O19 |
0.422 |
|
| 2015 |
Page DB, Diab A, Yuan J, Dong Z, Soloman SB, Patil S, Hudis CA, Wolchok JD, Norton L, McArthur HL. Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S1-O6 |
0.46 |
|
| 2015 |
Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, ... ... Wolchok J, et al. Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-15-01 |
0.452 |
|
| 2015 |
Wolchok JD. Abstract IA27: Combination immunotherapy for melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-Ia27 |
0.48 |
|
| 2015 |
Hodi FS, Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette G, Meyer N, Giguere J, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama A, ... ... Wolchok JD, et al. Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone Cancer Research. 75: 2860-2860. DOI: 10.1158/1538-7445.Am2015-2860 |
0.405 |
|
| 2015 |
Urba WJ, Martín-Algarra S, Callahan M, Wolchok JD, Sharfman WH, Sosman JA, Bhatia S, Hwu W, Gajewski TF, Slingluff CL, Shen Y, Horak CE, Hodi FS. Abstract 2855: Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma Cancer Research. 75: 2855-2855. DOI: 10.1158/1538-7445.Am2015-2855 |
0.437 |
|
| 2015 |
Daud A, Joshua AM, Ribas A, Robert C, Hodi FS, Wolchok J, Hwu W, Weber JS, Gangadhar TC, Joseph R, Dronca R, Patnaik A, Zarour H, Kefford R, Lindia J, et al. A Pooled analysis of 655 patients with advanced melanoma enrolled in keynote-001 : long-term efficacy of pembrolizumab (mk-3475) Asia-Pacific Journal of Clinical Oncology. 11: 43-43. DOI: 10.1111/Ajco.12396 |
0.312 |
|
| 2015 |
Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C, Lao C, Schadendorf D, Ferrucci P, Smylie M, Dummer R, Hill A, Haanen J, Maio M, McArthur G, et al. CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) Annals of Oncology. 26: vi28. DOI: 10.1093/Annonc/Mdv337.08 |
0.345 |
|
| 2015 |
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Hogg D, Hill A, Carlino MS, Wolter P, Lebbé C, Schachter J, Thomas L, Hassel JC, ... ... Wolchok JD, et al. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31822-6 |
0.337 |
|
| 2015 |
Page D, Yuan J, Dong Z, Ginsberg A, Wong P, Emerson R, Sung J, Comstock C, Mu Z, Solomon S, Diab A, Durack J, Maybody M, Erinjeri J, Brogi E, ... ... Wolchok J, et al. FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer Journal of Vascular and Interventional Radiology. 26: S131. DOI: 10.1016/J.Jvir.2014.12.352 |
0.369 |
|
| 2015 |
Ribas A, Wolchok JD, Robert C, Kefford R, Hamid O, Daud A, Hwu W-, Weber JS, Joshua AM, Gangadhar TC, Patnaik A, Hersey P, Dronca R, Zarour H, Gergich K, et al. P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma European Journal of Cancer. 51. DOI: 10.1016/J.Ejca.2015.06.072 |
0.421 |
|
| 2014 |
Kluger H, Sznol M, Callahan M, Postow M, Gordon R, Segal NH, Rizvi N, Lesokhin A, Atkins MB, Kirkwood J, Burke M, Ralabate A, Rivera A, Kronenberg S, Agunwamba BU, ... ... Wolchok J, et al. 1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv374. PMID 28172011 DOI: 10.1093/Annonc/Mdu344.1 |
0.363 |
|
| 2014 |
Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA9008. PMID 28141989 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba9008 |
0.4 |
|
| 2014 |
Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, Burke MM, Ralabate AL, Rivera AL, Kronenberg SA, Agunwamba B, Feely W, ... ... Wolchok JD, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA9003. PMID 28141981 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba9003 |
0.368 |
|
| 2014 |
Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu WJ, Gangadhar TC, Patnaik A, Joshua AM, Hersey P, Weber JS, Dronca RS, Zarour HM, Gergich K, Li XN, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA9000. PMID 28141979 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba9000 |
0.341 |
|
| 2014 |
Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Sacchini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, et al. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 64. PMID 28141090 DOI: 10.1200/Jco.2014.32.26_Suppl.64 |
0.44 |
|
| 2014 |
Zamarin D, Wolchok JD. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular Therapy Oncolytics. 1: 14004. PMID 27119094 DOI: 10.1038/Mto.2014.4 |
0.448 |
|
| 2014 |
Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in Oncology. 4: 385. PMID 25642417 DOI: 10.3389/Fonc.2014.00385 |
0.394 |
|
| 2014 |
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Wolchok JD, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998 |
0.43 |
|
| 2014 |
Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature. 515: 496-8. PMID 25428495 DOI: 10.1038/515496A |
0.43 |
|
| 2014 |
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, ... ... Wolchok JD, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine. 371: 2189-99. PMID 25409260 DOI: 10.1056/Nejmoa1406498 |
0.492 |
|
| 2014 |
Merghoub T, Wolchok JD. Immunotherapy and the belly of the beast. Journal of Experimental Medicine. 211: 2327-2328. PMID 25403805 DOI: 10.1084/Jem.21112Insight3 |
0.343 |
|
| 2014 |
Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease Journal For Immunotherapy of Cancer. 2: 35-35. PMID 25349698 DOI: 10.1186/S40425-014-0035-Z |
0.42 |
|
| 2014 |
Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. British Journal of Cancer. 111: 2214-9. PMID 25211661 DOI: 10.1038/Bjc.2014.348 |
0.437 |
|
| 2014 |
Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2277-84. PMID 25210016 DOI: 10.1093/Annonc/Mdu441 |
0.328 |
|
| 2014 |
McDermott D, Lebbé C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews. 40: 1056-64. PMID 25060490 DOI: 10.1016/J.Ctrv.2014.06.012 |
0.368 |
|
| 2014 |
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 384: 1109-17. PMID 25034862 DOI: 10.1016/S0140-6736(14)60958-2 |
0.345 |
|
| 2014 |
Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. Journal For Immunotherapy of Cancer. 2: 19. PMID 24991413 DOI: 10.1186/2051-1426-2-19 |
0.385 |
|
| 2014 |
Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, ... ... Wolchok JD, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. Jama. 311: 2397-405. PMID 24938562 DOI: 10.1001/Jama.2014.6096 |
0.324 |
|
| 2014 |
Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. European Journal of Cancer (Oxford, England : 1990). 50: 2099-107. PMID 24930625 DOI: 10.1016/J.Ejca.2014.03.289 |
0.333 |
|
| 2014 |
Naidoo J, Page DB, Wolchok JD. Immune checkpoint blockade. Hematology/Oncology Clinics of North America. 28: 585-600. PMID 24880949 DOI: 10.1016/J.Hoc.2014.02.002 |
0.395 |
|
| 2014 |
Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal For Immunotherapy of Cancer. 2: 7. PMID 24855562 DOI: 10.1186/2051-1426-2-7 |
0.438 |
|
| 2014 |
Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, Rasalan T, Adamow M, Yuan J, Wong P, Altan-Bonnet G, Wolchok JD, Lesokhin AM. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunology Research. 2: 812-21. PMID 24844912 DOI: 10.1158/2326-6066.Cir-14-0013 |
0.65 |
|
| 2014 |
Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, Tiwari S, Maughan MF, Olmsted R, Wolchok JD, Merghoub T. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunology Research. 2: 448-58. PMID 24795357 DOI: 10.1158/2326-6066.Cir-13-0220 |
0.457 |
|
| 2014 |
Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events Journal of the American Academy of Dermatology. 71: 161-169. PMID 24767731 DOI: 10.1016/J.Jaad.2014.02.035 |
0.433 |
|
| 2014 |
Tkach KE, Barik D, Voisinne G, Malandro N, Hathorn MM, Cotari JW, Vogel R, Merghoub T, Wolchok J, Krichevsky O, Altan-Bonnet G. T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. Elife. 3: e01944. PMID 24719192 DOI: 10.7554/Elife.01944 |
0.631 |
|
| 2014 |
Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science Translational Medicine. 6: 230ra45. PMID 24695685 DOI: 10.1126/Scitranslmed.3008002 |
0.387 |
|
| 2014 |
Budhu S, Wolchok J, Merghoub T. The importance of animal models in tumor immunity and immunotherapy Current Opinion in Genetics & Development. 24: 46-51. PMID 24657536 DOI: 10.1016/J.Gde.2013.11.008 |
0.454 |
|
| 2014 |
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer. 21: 371-81. PMID 24610577 DOI: 10.1530/Erc-13-0499 |
0.39 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/Scitranslmed.3008095 |
0.441 |
|
| 2014 |
Murphy JT, Burey AP, Beebe AM, Gu D, Presta LG, Merghoub T, Wolchok JD. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice Blood. 123: 2172-2180. PMID 24558202 DOI: 10.1182/Blood-2013-12-544742 |
0.379 |
|
| 2014 |
Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, ... ... Wolchok JD, et al. Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. The Journal of Investigative Dermatology. 134: 2202-11. PMID 24522433 DOI: 10.1038/Jid.2014.85 |
0.328 |
|
| 2014 |
Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, Russell V, Gordon RA, Vyas S, Yuan J, Gupta A, Wigginton JM, Rosen N, Merghoub T, Jure-Kunkel M, ... Wolchok JD, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunology Research. 2: 70-9. PMID 24416731 DOI: 10.1158/2326-6066.Cir-13-0160 |
0.356 |
|
| 2014 |
Postow MA, Yuan J, Kitano S, Lesokhin AM, Wolchok JD. Markers for Anti-Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma Methods of Molecular Biology. 1102: 83-95. PMID 24258975 DOI: 10.1007/978-1-62703-727-3_6 |
0.457 |
|
| 2014 |
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annual Review of Medicine. 65: 185-202. PMID 24188664 DOI: 10.1146/Annurev-Med-092012-112807 |
0.44 |
|
| 2014 |
Tkach KE, Barik D, Voisinne G, Malandro N, Hathorn MM, Cotari JW, Vogel R, Merghoub T, Wolchok J, Krichevsky O, Altan-Bonnet G. Author response: T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks Elife. DOI: 10.7554/Elife.01944.018 |
0.635 |
|
| 2014 |
Postow M, Manuel M, Wong P, Yuan J, Courtier A, Pasqual N, Wolchok JD. T cell receptor diversity evaluation to predict patient response to ipilimumab in metastatic melanoma F1000research. 5. DOI: 10.7490/F1000Research.1097399.1 |
0.365 |
|
| 2014 |
Simoes P, Wolchok J, Chapman P, Gelwan MG. Different Faces of Hepatotoxicity in Patients With Metastatic Melanoma on Combination Vemurafenib and Ipilimumab Therapy: 1336 The American Journal of Gastroenterology. 109. DOI: 10.14309/00000434-201410002-01336 |
0.314 |
|
| 2014 |
Bauer TM, Papadopoulos KP, Autio KA, Ott PA, Whiteside M, Oft M, Infante JR, Hodi FS, Wolchok JD. A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3126 |
0.39 |
|
| 2014 |
Callahan MK, Ott PA, Odunsi K, Bertolini SV, Pan LS, Venhaus RR, Karakunnel JJ, Hodi FS, Wolchok JD. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3120 |
0.463 |
|
| 2014 |
Segal NH, Hodi FS, Sanborn RE, Gajewski T, Wolchok JD, Urba WJ, Fox BA, Topalian SL, Pardoll DM, Kollia G, McDonald D, Kim SY, Sharfman WH. A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3115 |
0.477 |
|
| 2014 |
Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, Hoeller C, Dummer R, Pehamberger H, Wolchok JD, Postow MA. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. Journal of Clinical Oncology. 32: 9096-9096. DOI: 10.1200/Jco.2014.32.15_Suppl.9096 |
0.399 |
|
| 2014 |
Ariyan CE, Lefkowitz RA, Panageas K, Callahan MK, Misholy O, Bello D, Fisher C, Kotin A, Siegelbaum R, Coit DG, Wolchok JD, Brady MS. Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma. Journal of Clinical Oncology. 32: 9078-9078. DOI: 10.1200/Jco.2014.32.15_Suppl.9078 |
0.34 |
|
| 2014 |
Bitas C, Shoushtari AN, Bluth MJ, Bhuchar G, Hester RH, Romero J, Fitzpatrick L, Lefkowitz RA, Panageas K, Schwartz GK, Callahan MK, Postow MA, Wolchok JD, Chapman PB, Carvajal RD. The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma. Journal of Clinical Oncology. 32: 9073-9073. DOI: 10.1200/Jco.2014.32.15_Suppl.9073 |
0.341 |
|
| 2014 |
Johnson DB, Peng C, Abramson RG, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Ipilimumab in acral melanoma: A retrospective review. Journal of Clinical Oncology. 32: 9056-9056. DOI: 10.1200/Jco.2014.32.15_Suppl.9056 |
0.382 |
|
| 2014 |
Atkins MB, Kudchadkar RR, Sznol M, McDermott DF, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, Slingluff CL, Ernstoff MS, Fay JW, Friedlander PA, Gajewski T, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. Journal of Clinical Oncology. 32: 9001-9001. DOI: 10.1200/Jco.2014.32.15_Suppl.9001 |
0.359 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park J, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Journal of Clinical Oncology. 32: 3051-3051. DOI: 10.1200/Jco.2014.32.15_Suppl.3051 |
0.423 |
|
| 2014 |
Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, ... Wolchok JD, et al. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). Journal of Clinical Oncology. 32: 3021-3021. DOI: 10.1200/Jco.2014.32.15_Suppl.3021 |
0.388 |
|
| 2014 |
Joseph RW, Elassaiss-Schaap J, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Hwu W, Kefford R, Hersey P, Weber JS, Patnaik A, De Alwis DP, et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology. 32: 3015-3015. DOI: 10.1200/Jco.2014.32.15_Suppl.3015 |
0.393 |
|
| 2014 |
Hodi FS, Ribas A, Daud A, Hamid O, Robert C, Kefford R, Hwu W, Gangadhar TC, Joshua AM, Hersey P, Weber JS, Dronca RS, Perrone AM, Gammage L, Hille D, ... ... Wolchok JD, et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology. 32: 3006-3006. DOI: 10.1200/Jco.2014.32.15_Suppl.3006 |
0.429 |
|
| 2014 |
Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, Joshua AM, Hodi FS, Gangadhar TC, Hersey P, Weber JS, Dronca RS, Patnaik A, Zarour HM, Dolled-Filhart M, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology. 32: 3005-3005. DOI: 10.1200/Jco.2014.32.15_Suppl.3005 |
0.38 |
|
| 2014 |
Snyder Charen A, Makarov V, Merghoub T, Walsh L, Yuan J, Miller M, Kannan K, Postow MA, Elipenahli C, Liu C, Wolchok JD, Chan TA. The neoantigen landscape underlying clinical response to ipilimumab. Journal of Clinical Oncology. 32: 3003-3003. DOI: 10.1200/Jco.2014.32.15_Suppl.3003 |
0.403 |
|
| 2014 |
Hamid O, Robert C, Ribas A, Wolchok JD, Hodi FS, Kefford R, Joshua AM, Hwu W, Gangadhar TC, Patnaik A, Hersey P, Weber JS, Joseph RW, Gergich K, Li X, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). Journal of Clinical Oncology. 32: 3000-3000. DOI: 10.1200/Jco.2014.32.15_Suppl.3000 |
0.33 |
|
| 2014 |
Puzanov I, Callahan MK, Linette GP, Patel SP, Luke JJ, Sosman JA, Wolchok JD, Hamid O, Minor DR, Orford KW, Hug BA, Ma B, Matthys GM, Hoos A. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). Journal of Clinical Oncology. 32: 2511-2511. DOI: 10.1200/Jco.2014.32.15_Suppl.2511 |
0.323 |
|
| 2014 |
Zappasodi R, Budhu S, Schaer D, Yang X, Zhong H, Merghoub T, Wolchok JD. Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P242 |
0.458 |
|
| 2014 |
Holmgaard RB, Zamarin D, Munn DH, Merghoub T, Wolchok JD. Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P212 |
0.403 |
|
| 2014 |
Budhu S, Schaer D, Li Y, Houghton A, Silverstein S, Merghoub T, Wolchok JD. Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P192 |
0.434 |
|
| 2014 |
Page DB, McArthur H, Dong Z, Wong P, Emerson R, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, ... ... Wolchok JD, et al. Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P138 |
0.456 |
|
| 2014 |
Zamarin D, Holmgaard RB, Plitt T, Allison J, Merghoub T, Wolchok JD. Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P132 |
0.44 |
|
| 2014 |
Page DB, Naidoo J, Momtaz P, Bogatch K, Kuk D, Panageas K, Yuan J, Wolchok JD, Postow M. Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience Journal For Immunotherapy of Cancer. 2: 117. DOI: 10.1186/2051-1426-2-S3-P117 |
0.326 |
|
| 2014 |
Hodi FS, Ribas A, Daud A, Hamid O, Robert C, Kefford R, Hwu W, Gangadhar TC, Joshua AM, Hersey P, Weber J, Joseph RW, Zarour H, Dronca R, Gammage L, ... ... Wolchok JD, et al. Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC) Journal For Immunotherapy of Cancer. 2: 103. DOI: 10.1186/2051-1426-2-S3-P103 |
0.378 |
|
| 2014 |
Postow M, Manuel M, Wong P, Yuan J, Noel M, Courtier A, Pasqual N, Wolchok JD. T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma. Journal For Immunotherapy of Cancer. 2: 1-2. DOI: 10.1186/2051-1426-2-S3-O8 |
0.402 |
|
| 2014 |
Postow MA, Cardona DM, Taube JM, Anders RA, Taylor CR, Wolchok JD, Callahan MK, Curran MA, Lesokhin AM, Grosso JF, Horak CE, Cogswell J, Simon JS, Gupta AK, Sznol M. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab Journal of Translational Medicine. 12: O8. DOI: 10.1186/1479-5876-12-S1-O8 |
0.388 |
|
| 2014 |
Wolchok JD. Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Pl02-03 |
0.518 |
|
| 2014 |
Daud AI, Hamid O, Ribas A, Hodi FS, Hwu W, Kefford R, Wolchok J, Hersey P, Weber JS, Joseph R, Gangadhar TC, Dronca RS, Patnaik A, Zarour H, Joshua AM, et al. Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct104 |
0.409 |
|
| 2014 |
Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford RF, Daud A, Wolchok JD, Hwu W, Gangadhar TC, Patnaik A, Hersey P, Dronca R, Zarour H, Ge Y, et al. Lba34Pembrolizumab (Pembro; Mk-3475) For Advanced Melanoma (Mel): Randomized Comparison Of Two Dosing Schedules Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.42 |
0.318 |
|
| 2014 |
Daud A, Hamid O, Robert C, Hodi FS, Wolchok JD, Hwu WJ, Weber JS, Kefford R, Hersey P, Joshua AM, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, et al. 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) European Journal of Cancer. 50: 48-49. DOI: 10.1016/S0959-8049(14)70266-7 |
0.316 |
|
| 2013 |
Solomon SB, Comstock C, Maybody M, Sacchini V, Durack JC, Blum B, Yuan J, Patil S, Neville DA, Sung JS, Kotin A, Morris EA, Brogi E, Morrow M, Wolchok JD, et al. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 67. PMID 28136692 DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3120 |
0.403 |
|
| 2013 |
Gyorki DE, Callahan M, Wolchok JD, Ariyan CE. The delicate balance of melanoma immunotherapy. Clinical & Translational Immunology. 2: e5. PMID 25505953 DOI: 10.1038/Cti.2013.5 |
0.399 |
|
| 2013 |
Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. Journal For Immunotherapy of Cancer. 1: 20. PMID 24829756 DOI: 10.1186/2051-1426-1-20 |
0.354 |
|
| 2013 |
Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunology Research. 1: 229-34. PMID 24777852 DOI: 10.1158/2326-6066.Cir-13-0020 |
0.389 |
|
| 2013 |
Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunology Research. 1: 92-8. PMID 24777500 DOI: 10.1158/2326-6066.Cir-13-0082 |
0.394 |
|
| 2013 |
Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunology Research. 1: 320-31. PMID 24416730 DOI: 10.1158/2326-6066.Cir-13-0086 |
0.427 |
|
| 2013 |
Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunology Research. 1: 235-44. PMID 24396833 DOI: 10.1158/2326-6066.Cir-13-0068 |
0.42 |
|
| 2013 |
Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, et al. Enhanced responses to tumor immunization following total body irradiation are time-dependent. Plos One. 8: e82496. PMID 24349298 DOI: 10.1371/Journal.Pone.0082496 |
0.461 |
|
| 2013 |
Page DB, Postow MA, Callahan MK, Wolchok JD. Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Current Oncology Reports. 15: 500-8. PMID 23933888 DOI: 10.1007/S11912-013-0337-1 |
0.399 |
|
| 2013 |
Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, ... ... Wolchok JD, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 119: 3687-95. PMID 23913718 DOI: 10.1002/Cncr.28282 |
0.385 |
|
| 2013 |
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of Experimental Medicine. 210: 1695-710. PMID 23897981 DOI: 10.1084/Jem.20130579 |
0.429 |
|
| 2013 |
Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, et al. Two Distinct Categories of Focal Deletions in Cancer Genomes. Plos One. 8: e66264. PMID 23805207 DOI: 10.1371/Journal.Pone.0066264 |
0.332 |
|
| 2013 |
Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences. 1291: 1-13. PMID 23772560 DOI: 10.1111/Nyas.12180 |
0.461 |
|
| 2013 |
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of Experimental Medicine. 210: 1389-402. PMID 23752227 DOI: 10.1084/Jem.20130066 |
0.483 |
|
| 2013 |
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, et al. Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine. 369: 122-33. PMID 23724867 DOI: 10.1056/Nejmoa1302369 |
0.448 |
|
| 2013 |
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine. 369: 134-44. PMID 23724846 DOI: 10.1056/Nejmoa1305133 |
0.459 |
|
| 2013 |
Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, ... ... Wolchok JD, et al. Ipilimumab for patients with advanced mucosal melanoma. The Oncologist. 18: 726-32. PMID 23716015 DOI: 10.1634/Theoncologist.2012-0464 |
0.435 |
|
| 2013 |
Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Annals of Surgical Oncology. 20: 3106-11. PMID 23681603 DOI: 10.1245/S10434-013-2999-1 |
0.359 |
|
| 2013 |
Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. Journal of Leukocyte Biology. 94: 41-53. PMID 23667165 DOI: 10.1189/Jlb.1212631 |
0.413 |
|
| 2013 |
Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2174-80. PMID 23666915 DOI: 10.1093/Annonc/Mdt161 |
0.402 |
|
| 2013 |
Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Current Opinion in Immunology. 25: 291-296. PMID 23561594 DOI: 10.1016/J.Coi.2013.02.011 |
0.406 |
|
| 2013 |
Lesokhin AM, Merghoub T, Wolchok JD. Myeloid-derived suppressor cells and the efficacy of CD8+ T-cell immunotherapy Oncoimmunology. 2. PMID 23525353 DOI: 10.4161/Onci.22764 |
0.44 |
|
| 2013 |
Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells Clinical Cancer Research. 19: 1044-1053. PMID 23460535 DOI: 10.1158/1078-0432.Ccr-12-2065 |
0.448 |
|
| 2013 |
Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1009-20. PMID 23460532 DOI: 10.1158/1078-0432.Ccr-12-2982 |
0.469 |
|
| 2013 |
Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2257-64. PMID 23444215 DOI: 10.1158/1078-0432.Ccr-12-3476 |
0.402 |
|
| 2013 |
Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clinics in Dermatology. 31: 191-9. PMID 23438382 DOI: 10.1016/J.Clindermatol.2012.08.006 |
0.451 |
|
| 2013 |
Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational New Drugs. 31: 425-34. PMID 22864522 DOI: 10.1007/S10637-012-9862-2 |
0.417 |
|
| 2013 |
Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response International Journal of Radiation Oncology Biology Physics. 85: 293-295. PMID 22560555 DOI: 10.1016/J.Ijrobp.2012.03.017 |
0.453 |
|
| 2013 |
Puzanov I, Wolchok JD, Ascierto PA, Hamid O, Margolin K. Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases Expert Review of Dermatology. 8: 479-487. DOI: 10.1586/17469872.2013.835922 |
0.411 |
|
| 2013 |
Diab A, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Sung JS, Blum B, Neville DA, Kotin A, Yuan J, Patil S, Morris EA, Brogi E, Morrow M, ... Wolchok JD, et al. A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC). Journal of Clinical Oncology. 31: TPS3120-TPS3120. DOI: 10.1200/JCO.2013.31.15_SUPPL.TPS3120 |
0.303 |
|
| 2013 |
Sosman JA, Martin-Algarra S, Wolchok JD, Sharfman WH, Bhatia S, Hodi FS, Hwu W, Gajewski T, Slingluff CL, Kaufman H, Gupta M, McGirr A, Horak CE, Ahlers CM, Wigginton JM, et al. An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL). Journal of Clinical Oncology. 31: TPS3114-TPS3114. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3114 |
0.476 |
|
| 2013 |
Sanborn RE, Sharfman WH, Segal NH, Hodi FS, Wolchok JD, Urba WJ, Fox BA, Topalian SL, Pardoll DM, Covello KL, McDonald D, Kim SY, Gupta AK, Wigginton JM, Gajewski T. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3110 |
0.452 |
|
| 2013 |
Melero I, Gangadhar TC, Kohrt HE, Segal NH, Logan T, Urba WJ, Hodi FS, Ott PA, Perez-Gracia JL, Wolchok JD, Shah A, Kurland JF, Cohen LJ, Levy R, Wigginton JM, et al. A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3107 |
0.462 |
|
| 2013 |
Harding JJ, Catalanotti F, Yaqubie A, McDermott GC, Kersellius R, Merghoub T, Carvajal RD, D'Angelo SP, Dickson MA, Schwartz GK, Wolchok JD, Berger MF, Solit DB, Chapman PB. Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets). Journal of Clinical Oncology. 31: 9060-9060. DOI: 10.1200/Jco.2013.31.15_Suppl.9060 |
0.358 |
|
| 2013 |
Neyns B, Weber JS, Lebbé C, Maio M, Harmankaya K, Hamid O, O'Day S, Chin KM, McDowell DO, Cykowski L, McHenry B, Wolchok JD. Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials. Journal of Clinical Oncology. 31: 9059-9059. DOI: 10.1200/Jco.2013.31.15_Suppl.9059 |
0.379 |
|
| 2013 |
Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day S, Chin KM, McDowell DO, Cykowski L, McHenry B, Wolchok JD. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. Journal of Clinical Oncology. 31: 9053-9053. DOI: 10.1200/Jco.2013.31.15_Suppl.9053 |
0.311 |
|
| 2013 |
Postow MA, Chasalow SD, Yuan J, Kuk D, Panageas KS, Cheng M, Shahabi V, Berman DM, Wolchok JD. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. Journal of Clinical Oncology. 31: 9052-9052. DOI: 10.1200/Jco.2013.31.15_Suppl.9052 |
0.397 |
|
| 2013 |
Schindler K, Harmankaya K, Postow MA, Frantal S, Bello D, Ariyan CE, Michielin OA, Hoeller C, Pehamberger H, Wolchok JD. Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody. Journal of Clinical Oncology. 31: 9024-9024. DOI: 10.1200/Jco.2013.31.15_Suppl.9024 |
0.398 |
|
| 2013 |
Wolchok JD, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba B, Feely W, Hong Q, et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). Journal of Clinical Oncology. 31: 9012-9012. DOI: 10.1200/Jco.2013.31.15_Suppl.9012 |
0.401 |
|
| 2013 |
Ribas A, Robert C, Daud A, Hodi FS, Wolchok JD, Kefford R, Patnaik A, Hwu W, Weber JS, Joshua A, Hersey P, Gangadhar TC, Joseph RW, Dronca RS, Zarour HM, et al. Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. Journal of Clinical Oncology. 31: 9009-9009. DOI: 10.1200/Jco.2013.31.15_Suppl.9009 |
0.38 |
|
| 2013 |
Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, ... ... Wolchok JD, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Journal of Clinical Oncology. 31: 3003-3003. DOI: 10.1200/Jco.2013.31.15_Suppl.3003 |
0.446 |
|
| 2013 |
Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wolchok JD, Hodi FS. Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab Journal For Immunotherapy of Cancer. 1: 247. DOI: 10.1186/2051-1426-1-S1-P247 |
0.332 |
|
| 2013 |
Budhu S, Schaer D, Li Y, Houghton A, Silverstein S, Merghoub T, Wolchok J. Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment Journal For Immunotherapy of Cancer. 1: P173. DOI: 10.1186/2051-1426-1-S1-P173 |
0.44 |
|
| 2013 |
Zamarin D, Holmgaard R, Subudhi S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O9 |
0.45 |
|
| 2013 |
Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, ... ... Wolchok JD, et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O6 |
0.437 |
|
| 2013 |
Moskalenko M, Pan M, Hashimoto D, Mortha A, Bernardo SG, Leboeuf M, Houghton A, Wolchok J, Burakoff S, Merad M, Saenger YM. Abstract A43: Therapeutic efficacy of antitumor monoclonal antibodies combined with chemotherapy depends on innate immunity and NK1.1- innate lymphoid cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-A43 |
0.454 |
|
| 2013 |
Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB. Abstract 2284: Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma. Cancer Research. 73: 2284-2284. DOI: 10.1158/1538-7445.Am2013-2284 |
0.381 |
|
| 2013 |
Stam AG, Santegoets SJ, Eertwegh AJvd, Scheper RJ, Lougheed SM, Gall H, Jooss K, Sacks N, Harding T, Hege K, Lowy I, Gnjatic S, Wolchok JD, Gerritsen WR, Gruijl TDd. Abstract 1229: Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab. Cancer Research. 73: 1229-1229. DOI: 10.1158/1538-7445.Am2013-1229 |
0.419 |
|
| 2013 |
Diab A, Solomon S, Comstock C, Maybody M, Sacchini V, Durack J, Blum B, Yuan J, Patil S, Neville D, Sung J, Kotin A, Morris E, Brogi E, Morrow M, ... Wolchok J, et al. Abstract P4-13-01: A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-13-01 |
0.326 |
|
| 2013 |
Callahan MK, Postow MA, Wolchok JD. Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. 287-307. DOI: 10.1016/B978-0-12-394296-8.00019-1 |
0.331 |
|
| 2013 |
Callahan MK, Wolchok JD, Allison JP, Sharma P. Immune co-signaling to treat cancer Cancer Immunotherapy: Paradigms, Practice and Promise. 2147483647: 211-280. DOI: 10.1007/978-1-4614-4732-0_8 |
0.438 |
|
| 2012 |
Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 120: 4882-91. PMID 23012326 DOI: 10.1182/Blood-2012-06-437236 |
0.383 |
|
| 2012 |
Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of Experimental Medicine. 209: 2113-26. PMID 23008334 DOI: 10.1084/Jem.20120532 |
0.423 |
|
| 2012 |
Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma Annals of Oncology. 23. PMID 22918923 DOI: 10.1093/Annonc/Mds258 |
0.416 |
|
| 2012 |
Peinado H, Ale?kovi? M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, ... ... Wolchok JD, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine. 18: 883-91. PMID 22635005 DOI: 10.1038/Nm.2753 |
0.306 |
|
| 2012 |
Avogadri F, Wolchok JD. Selecting antigens for cancer vaccines. Nature Biotechnology. 30: 328-329. PMID 22491282 DOI: 10.1038/Nbt.2174 |
0.316 |
|
| 2012 |
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet. Oncology. 13: 459-65. PMID 22456429 DOI: 10.1016/S1470-2045(12)70090-6 |
0.354 |
|
| 2012 |
Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer Journal (Sudbury, Mass.). 18: 153-9. PMID 22453017 |
0.376 |
|
| 2012 |
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nature Reviews. Cancer. 12: 278-87. PMID 22437872 DOI: 10.1038/Nrc3236 |
0.363 |
|
| 2012 |
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, ... ... Wolchok JD, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine. 366: 925-31. PMID 22397654 DOI: 10.1056/Nejmoa1112824 |
0.458 |
|
| 2012 |
Postow MA, Callahan MK, Wolchok JD. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1821-3. PMID 22338019 DOI: 10.1158/1078-0432.Ccr-12-0409 |
0.423 |
|
| 2012 |
Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Current Opinion in Immunology. 24: 217-24. PMID 22245556 DOI: 10.1016/J.Coi.2011.12.011 |
0.374 |
|
| 2012 |
Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Research. 72: 876-86. PMID 22174368 DOI: 10.1182/Blood.V118.21.2171.2171 |
0.422 |
|
| 2012 |
Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, ... ... Wolchok J, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 31: 446-57. PMID 21725359 DOI: 10.1038/Onc.2011.250 |
0.376 |
|
| 2012 |
Pennock GK, Waterfield W, Wolchok JD. Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses? American Journal of Clinical Oncology. 35: 606-611. PMID 21336089 DOI: 10.1097/Coc.0B013E318209Cda9 |
0.413 |
|
| 2012 |
Ribas A, Hodi FS, Kurland JF, Shahabi V, Francis S, Konto C, Joe AK, Lainas I, Wolchok JD. CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps8603 |
0.411 |
|
| 2012 |
Carvajal RD, Ambrosini G, Wolchok JD, Chapman PB, Dickson MA, D'Angelo SP, Bluth MJ, Paucar D, Fusco A, Bohr D, Roman RA, Montefusco M, Doyle LA, Marr B, Abramson DH, et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. Journal of Clinical Oncology. 30: 8598-8598. DOI: 10.1200/Jco.2012.30.15_Suppl.8598 |
0.389 |
|
| 2012 |
Gyorki DE, Yuan J, Mu Z, Zaidi B, Gallardo HF, Brady MS, Gutin PH, Coit DG, Wolchok JD, Ariyan CE. Surgery for patients receiving ipilimumab: Safety profile and immunological insights. Journal of Clinical Oncology. 30: 8583-8583. DOI: 10.1200/Jco.2012.30.15_Suppl.8583 |
0.378 |
|
| 2012 |
Postow MA, Yuan J, Panageas K, Bogatch K, Callahan M, Cheng M, Schroeder SEA, Kendle RF, Harding JJ, Dickson MA, D'Angelo SP, Carvajal RD, Schwartz GK, Wolchok JD. Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg). Journal of Clinical Oncology. 30: 8575-8575. DOI: 10.1200/Jco.2012.30.15_Suppl.8575 |
0.331 |
|
| 2012 |
Khan SA, Callahan M, Postow MA, Chapman PB, Schwartz GK, Dickson MA, D'Angelo SP, Luke JJ, Bluth MJ, Roman RA, Montefusco M, Barker CA, Abramson DH, Wolchok JD, Carvajal RD. Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience. Journal of Clinical Oncology. 30: 8549-8549. DOI: 10.1200/Jco.2012.30.15_Suppl.8549 |
0.415 |
|
| 2012 |
Baurain J, Smylie M, Ascierto PA, Roman L, Houston S, Konto C, Chin KM, Chen T, Francis S, Wolchok JD. Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. Journal of Clinical Oncology. 30: 8539-8539. DOI: 10.1200/Jco.2012.30.15_Suppl.8539 |
0.419 |
|
| 2012 |
Harding JJ, Lacouture ME, Pulitzer M, Callahan M, Postow MA, Carvajal RD, Wolchok JD, Chapman PB. Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy. Journal of Clinical Oncology. 30: 8515-8515. DOI: 10.1200/Jco.2012.30.15_Suppl.8515 |
0.319 |
|
| 2012 |
Thomas L, Wolchok JD, Garbe C, Lebbe C, Bondarenko I, Rodrigues K, Konto C, Chin KM, Francis S, Robert C. Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study. Journal of Clinical Oncology. 30: 8512-8512. DOI: 10.1200/Jco.2012.30.15_Suppl.8512 |
0.383 |
|
| 2012 |
Hamid O, Hwu W, Richards JM, Weber JS, Wolchok JD, Sznol M, Minor DR, Pavlick AC, Urba WJ, Hodi FS, Yang A, Michener T, Balogh A, McDermott DF. Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. Journal of Clinical Oncology. 30: 8508-8508. DOI: 10.1200/Jco.2012.30.15_Suppl.8508 |
0.338 |
|
| 2012 |
Callahan M, Masters G, Katz J, Russell V, Roman RA, Montefusco M, Vyas S, Yuan J, Merghoub T, Gupta AK, Wigginton J, Jure-Kunkel M, Wolchok JD. The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade. Journal of Clinical Oncology. 30: 2521-2521. DOI: 10.1200/Jco.2012.30.15_Suppl.2521 |
0.425 |
|
| 2012 |
Kitano S, Postow MA, Cortez C, Rasalan T, Gallardo HF, Panageas K, Yuan J, Wolchok JD, Lesokhin AM. Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma. Journal of Clinical Oncology. 30: 2518-2518. DOI: 10.1200/Jco.2012.30.15_Suppl.2518 |
0.439 |
|
| 2012 |
Wolchok JD. Abstract SY32-02: Update on clinical results and correlative immunologic analysis of ipilimumab in patients with melanoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy32-02 |
0.512 |
|
| 2012 |
Diab A, McArthur H, Solomon S, Comstock C, Maybody M, Sacchini V, Durack J, Gucalp A, Yuan J, Patil S, Thorne A, Sung J, Kotin A, Morris E, Brogi E, ... ... Wolchok J, et al. Abstract OT3-1-01: A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Ot3-1-01 |
0.416 |
|
| 2012 |
Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer Journal. 18: 153-159. DOI: 10.1097/01.Ppo.0000581876.62921.87 |
0.479 |
|
| 2012 |
Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, McDowell DO, Cykowski L, McHenry MB, Wolchok JD. Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33712-1 |
0.331 |
|
| 2012 |
Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Francis S, Chin K, Wolchok J. Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33681-4 |
0.331 |
|
| 2012 |
Chasalow SD, Wolchok JD, Reck M, Maier S, Shahabi V. Effects of chemotherapy on ipilimumab-mediated increases in absolute lymphocyte count and activation of T cells Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32813-1 |
0.459 |
|
| 2012 |
Barker CA, Postow MA, Callahan MK, Khan S, Beal K, Parhar PK, Lee NY, Yamada Y, Wolchok JD. Tolerance and Efficacy of Extracranial Radiation Therapy During Ipilimumab Immunotherapy for Metastatic Melanoma International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1745 |
0.302 |
|
| 2011 |
Wolchok JD, Thomas L, Bondarenko IN, O'Day S, Weber JS, Garbe C, Francis S, Ibrahim RA, Hoos A, Robert C. Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: LBA5. PMID 28024022 DOI: 10.1200/Jco.2011.29.15_Suppl.Lba5 |
0.3 |
|
| 2011 |
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, ... ... Wolchok JD, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214 |
0.357 |
|
| 2011 |
Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research. 72: 1631-8. PMID 22126691 DOI: 10.2460/Ajvr.72.12.1631 |
0.318 |
|
| 2011 |
Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews. Cancer. 11: 805-12. PMID 22020206 DOI: 10.1038/Nrc3153 |
0.411 |
|
| 2011 |
Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer Journal (Sudbury, Mass.). 17: 372-8. PMID 21952288 DOI: 10.1097/Ppo.0B013E31823261Db |
0.422 |
|
| 2011 |
Schaer DA, Lesokhin AM, Wolchok JD. Hiding the road signs that lead to tumor immunity. The Journal of Experimental Medicine. 208: 1937-40. PMID 21948803 DOI: 10.1084/Jem.20111856 |
0.395 |
|
| 2011 |
Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, ... ... Wolchok JD, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America. 108: 16723-8. PMID 21933959 DOI: 10.1073/Pnas.1110814108 |
0.472 |
|
| 2011 |
Eidson M, Wahlstrom J, Beaulieu AM, Zaidi B, Carsons SE, Crow PK, Yuan J, Wolchok JD, Horsthemke B, Wieczorek D, Sant'Angelo DB. Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient. Plos One. 6: e24441. PMID 21915328 DOI: 10.1371/Journal.Pone.0024441 |
0.356 |
|
| 2011 |
Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, ... Wolchok JD, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine. 17: 1094-100. PMID 21873989 DOI: 10.1038/Nm.2438 |
0.346 |
|
| 2011 |
Schaer DA, Li Y, Merghoub T, Rizzuto GA, Shemesh A, Cohen AD, Li Y, Avogadri F, Toledo-Crow R, Houghton AN, Wolchok JD. Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. Plos One. 6: e21214. PMID 21731676 DOI: 10.1371/Journal.Pone.0021214 |
0.424 |
|
| 2011 |
Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, DeStanchina E, Longo V, Herz E, Iyer S, Wolchok J, Larson SM, Wiesner U, Bradbury MS. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. The Journal of Clinical Investigation. 121: 2768-80. PMID 21670497 DOI: 10.1172/Jci45600 |
0.343 |
|
| 2011 |
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 305: 2327-34. PMID 21642685 DOI: 10.1001/Jama.2011.746 |
0.39 |
|
| 2011 |
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, ... ... Wolchok JD, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine. 364: 2517-26. PMID 21639810 DOI: 10.1056/Nejmoa1104621 |
0.341 |
|
| 2011 |
Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunology, Immunotherapy : Cii. 60: 1137-46. PMID 21465316 DOI: 10.1007/S00262-011-1011-9 |
0.421 |
|
| 2011 |
Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, Carvajal RD. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2087-100. PMID 21444680 DOI: 10.1158/1078-0432.Ccr-10-3169 |
0.336 |
|
| 2011 |
Orlandi F, Guevara-Patiño JA, Merghoub T, Wolchok JD, Houghton AN, Gregor PD. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine. 29: 3646-54. PMID 21435405 DOI: 10.1016/J.Vaccine.2011.03.017 |
0.371 |
|
| 2011 |
Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of Veterinary Internal Medicine. 25: 94-99. PMID 21143299 DOI: 10.1111/J.1939-1676.2010.0627.X |
0.339 |
|
| 2011 |
Maus MV, Riviere I, Borquez-Ojeda O, Wang X, Yuan J, Merghoub T, Plotkin J, O’Reilly RJ, Wolchok JD, Sadelain M. Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma Blood. 118: 4309-4309. DOI: 10.1182/Blood.V118.21.4309.4309 |
0.416 |
|
| 2011 |
Saenger YM, Pan M, Hashimoto D, Glodny B, Shah S, Houghton AN, Merghoub T, Wolchok JD, Merad M. Abstract 4742: Anti-tyrosinase related protein 1 (TRP1) antibody combined with cyclophosphamide induces adaptive immunity against melanoma Cancer Research. 71: 4742-4742. DOI: 10.1158/1538-7445.Am2011-4742 |
0.486 |
|
| 2011 |
Robert C, Thomas L, Garbe C, Lebbe C, Baurain JF, Testori A, Maio M, Chen T, Hoos A, Wolchok J. 9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72527-8 |
0.308 |
|
| 2011 |
Perales M-, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos E, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, et al. Recombinant Human Interleukin-7 (CYT107) Promotes T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantion Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.244 |
0.31 |
|
| 2010 |
Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. Current Opinion in Investigational Drugs (London, England : 2000). 11: 1378-86. PMID 21154120 |
0.323 |
|
| 2010 |
Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Seminars in Oncology. 37: 473-84. PMID 21074063 DOI: 10.1053/J.Seminoncol.2010.09.001 |
0.458 |
|
| 2010 |
Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. Plos One. 5. PMID 20844763 DOI: 10.1371/Journal.Pone.0012670 |
0.46 |
|
| 2010 |
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. Journal of the National Cancer Institute. 102: 1388-97. PMID 20826737 DOI: 10.1093/Jnci/Djq310 |
0.424 |
|
| 2010 |
Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer Journal (Sudbury, Mass.). 16: 311-7. PMID 20693841 DOI: 10.1097/Ppo.0B013E3181Eb3381 |
0.472 |
|
| 2010 |
Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, ... Wolchok JD, et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4057-65. PMID 20647477 DOI: 10.1158/1078-0432.Ccr-10-1093 |
0.343 |
|
| 2010 |
Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy. 2: 367-79. PMID 20635901 DOI: 10.2217/Imt.10.21 |
0.47 |
|
| 2010 |
Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD. Modulation of CTLA-4 and GITR for cancer immunotherapy. Current Topics in Microbiology and Immunology. 344: 211-244. PMID 20563707 DOI: 10.1007/82_2010_49 |
0.469 |
|
| 2010 |
Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunology, Immunotherapy : Cii. 59: 1467-79. PMID 20532500 DOI: 10.1007/S00262-010-0871-8 |
0.337 |
|
| 2010 |
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, ... ... Wolchok JD, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine. 363: 711-23. PMID 20525992 DOI: 10.1056/Nejmoa1003466 |
0.378 |
|
| 2010 |
Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2861-71. PMID 20460488 DOI: 10.1158/1078-0432.Ccr-10-0569 |
0.4 |
|
| 2010 |
Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. Plos One. 5: e10436. PMID 20454651 DOI: 10.1371/Journal.Pone.0010436 |
0.432 |
|
| 2010 |
Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 116: 171-9. PMID 20400682 DOI: 10.1182/Blood-2009-10-250993 |
0.388 |
|
| 2010 |
Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 115: 4384-92. PMID 20154220 DOI: 10.1182/Blood-2009-11-251231 |
0.348 |
|
| 2010 |
O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, ... Wolchok JD, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 1712-7. PMID 20147741 DOI: 10.1093/Annonc/Mdq013 |
0.433 |
|
| 2010 |
Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 116: 1767-75. PMID 20143434 DOI: 10.1002/Cncr.24951 |
0.44 |
|
| 2010 |
Shah GD, Socci ND, Gold JS, Wolchok JD, Carvajal RD, Panageas KS, Viale A, Brady MS, Coit DG, Chapman PB. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 1718-22. PMID 20080829 DOI: 10.1093/Annonc/Mdp593 |
0.406 |
|
| 2010 |
Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, ... ... Wolchok JD, et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity. 10: 1. PMID 20052966 |
0.315 |
|
| 2010 |
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study The Lancet Oncology. 11: 155-164. PMID 20004617 DOI: 10.1016/S1470-2045(09)70334-1 |
0.34 |
|
| 2010 |
Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, Zelefsky MJ, Wolchok JD, Carvajal RD, Chapman PB, Wong RJ, Shaha AR, Kraus DH, Shah JP, Lee NY. Radiotherapy after surgical resection for head and neck mucosal melanoma. American Journal of Clinical Oncology. 33: 281-5. PMID 19823070 DOI: 10.1097/Coc.0B013E3181A879F5 |
0.311 |
|
| 2010 |
Ginsberg BA, Wolchok JD, Roman R, Gallardo HF, Chapman PB, Schwartz GK, Carvajal RD, Terzulli SL, Bewkes BB, Yuan JD. Immunologic response to xenogeneic gp100 DNA in melanoma patients: Comparison of particle-mediated epidermal delivery with intramuscular injection. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E13053 |
0.352 |
|
| 2010 |
Hodi FS, O'Day S, McDermott DF, Haanen JB, Robert C, Zhu X, Yellin MJ, Ibrahim RA, Hoos A, Wolchok JD. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. Journal of Clinical Oncology. 28: 8509-8509. DOI: 10.1200/Jco.2010.28.15_Suppl.8509 |
0.372 |
|
| Show low-probability matches. |